Dosage and administration of anti-C5 antibodies for the treatment of atypical hemolytic uraemic syndrome (aHUS) in pediatric patients
Administering anti-C5 antibodies to pediatric patients with aHUS inhibits complement activation, leading to improved clinical outcomes including thrombotic microangiopathy remission and renal function enhancement.
Patent Information
- Application Number
- JP2020567198
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-01-10
- Filing Date
- 2019-05-29
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2039-05-29
AI Technical Summary
Current treatments for atypical hemolytic uremic syndrome (aHUS) in pediatric patients are limited, and there is a need for improved therapeutic options to address the chronic uncontrolled complement activation that leads to severe morbidity and mortality in this population.
Administration of anti-C5 antibodies, such as ravulizumab or its antigen-binding fragments, following a specific clinical dosage regimen to inhibit complement activation and reduce inflammation and cell damage.
The treatment achieves effective remission of thrombotic microangiopathy, reduces serum creatinine levels, increases platelet count, and improves renal function, thereby decreasing the need for dialysis and enhancing quality of life in pediatric patients with aHUS.
Smart Images

Figure 0007577542000045 
Figure 0007577542000046 
Figure 0007577542000047
Abstract
Description
[Background technology]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application No. 62 / 680,121, filed June 4, 2018, and U.S. Provisional Patent Application No. 62 / 790,577, filed January 10, 2019. The entire contents of the aforementioned applications are incorporated by reference in their entirety. Sequence Listing
[0002] This application contains a Sequence Listing, which has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy was created on May 21, 2019, is named AXJ-237PC_SL.txt, and is 50,618 bytes in size.
[0003] The complement system works with the rest of the body's immune system to defend against invading cellular and viral pathogens. There are more than 30 complement system proteins, which exist as a complex collection of plasma proteins and membrane cofactors. Plasma proteins account for approximately 10% of the globulins in vertebrate serum. Complement components achieve their immune defense function by interacting in a complex but precise series of enzymatic cleavage and membrane binding events. The resulting complement cascade results in the production of products with opsonizing, immunomodulatory, and lytic activities.
[0004] A properly functioning complement system provides a potent defense against infectious microorganisms, but improper regulation or inappropriate activation of the complement pathway is involved in the pathology of a variety of disorders, including atypical hemolytic uraemic syndrome (aHUS), an ultra-rare disorder caused by chronically uncontrolled complement activation. The resulting inflammation and cellular damage lead to the devastating clinical manifestations of these diseases.
[0005] Hemolytic uremic syndrome (HUS) is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. HUS is classified into one of two types: diarrhea-associated HUS (DUS) + HUS; also called Shiga toxin-producing E. coli (STEC)-HUS or typical HUS) and non-diarrheal HUS or atypical HUS (aHUS). + HUS is the most common type, accounting for over 90% of cases, and is caused by the aforementioned illnesses involving Shiga toxin-producing bacteria, e.g., E. coli O157:H7.
[0006] Patients with aHUS, particularly pediatric and adolescent patients, are at risk for significant morbidity and mortality. Accordingly, it is an object of the compositions and methods described herein to provide improved treatments for human pediatric patients with aHUS. Summary of the Invention [Means for solving the problem]
[0007] Summary of the Invention Provided herein are compositions and methods for treating atypical hemolytic uremic syndrome (aHUS) in a pediatric patient (e.g., a patient under the age of 18) comprising administering to the patient an anti-C5 antibody or antigen-binding fragment thereof, which is administered (or is to be administered) according to a particular clinical dosing regimen (e.g., at a particular dose and according to a particular dosing schedule). In one embodiment, the pediatric patient has not been previously treated with a complement inhibitor (e.g., the patient is a complement inhibitor naive patient).
[0008] An exemplary anti-C5 antibody is ravulizumab (also known as ravulizumab, ALXN1210, and BNJ441 antibodies), which comprises heavy and light chains having the sequences set forth in SEQ ID NOs: 14 and 11, respectively, or antigen-binding fragments and variants thereof. In other embodiments, the antibody comprises the heavy and light chain complementarity determining regions (CDRs) or variable regions (VRs) of ravulizumab. The terms ravulizumab, BNJ441, and ALXN1210 may be used interchangeably throughout this document, but all refer to the same antibody. In one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the heavy chain variable (VH) region of ravulizumab having the sequence set forth in SEQ ID NO: 12, and the CDR1, CDR2, and CDR3 domains of the light chain variable (VL) region of ravulizumab having the sequence set forth in SEQ ID NO: 8. In another embodiment, the antibody comprises the heavy chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 19, 18, and 3, respectively, and the light chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 4, 5, and 6, respectively.
[0009] In another embodiment, the antibody comprises a VH region and a VL region having the amino acid sequences set forth in SEQ ID NO:12 and SEQ ID NO:8, respectively.
[0010] In another embodiment, the antibody comprises the heavy chain constant region set forth in SEQ ID NO:13.
[0011] In another embodiment, the antibody comprises a variant human Fc constant region that binds to the human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises substitutions of Met429Leu and Asn435Ser at residues corresponding to methionine 428 and asparagine 434, respectively, according to the EU numbering convention.
[0012] In another embodiment, the antibody comprises heavy chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 19, 18, and 3, respectively, and light chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 4, 5, and 6, respectively, and a variant human Fc constant region that binds to the human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises substitutions of Met429Leu and Asn435Ser at residues corresponding to methionine 428 and asparagine 434, respectively, according to the EU numbering convention.
[0013] In another embodiment, the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the BNJ421 antibody (described in PCT / US2015 / 019225 and US Pat. No. 9,079,949). In another embodiment, the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the 7086 antibody (see US Pat. Nos. 8,241,628 and 8,883,158). In another embodiment, the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the 8110 antibody (see US Pat. Nos. 8,241,628 and 8,883,158). In another embodiment, the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the 305LO5 antibody (see US Pat. No. US2016 / 0176954A1). In another embodiment, the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the SKY59 antibody (Fukuzawa, T., et al., Sci. Rep., 7:1080, 2017).
[0014] In another embodiment, the antibody competes for binding to the same epitope on C5 as any of the antibodies described herein and / or binds to the same epitope on C5 as any of the antibodies described herein. In another embodiment, the antibody has at least about 90% variable region amino acid sequence identity to any of the antibodies described herein (e.g., at least about 90%, 95% or 99% variable region identity to SEQ ID NO:12 and SEQ ID NO:8). In another embodiment, the antibody has an affinity dissociation constant (K DIn another embodiment, the antibody binds to human C5 at a K D In yet another embodiment, the K of the antibody or antigen-binding fragment thereof to human C5 at pH 6.0 and 25° C. is ≧10 nM. D ) / (K of an antibody or antigen-binding fragment thereof against human C5 at pH 7.4 and 25C D )] is greater than 25.
[0015] In another embodiment, the patient has already been treated with a different anti-C5 antibody or antigen-binding fragment thereof (eg, eculizumab) prior to treatment.
[0016] Pediatric patients treated according to the methods described herein are 18 years of age or younger. In one embodiment, the pediatric patient is 12 years of age or younger. In another embodiment, the pediatric patient is 6 years of age or younger. In another embodiment, the pediatric patient is 2 years of age or younger. In another embodiment, the pediatric patient is under the age of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 years of age.
[0017] In one embodiment, the dose of the anti-C5 antibody or antigen-binding fragment thereof is based on the weight of the pediatric patient. In one embodiment, for example, about 300 mg, about 600 mg, about 900 mg, about 1200 mg, about 2100 mg, about 2700 mg, about 3000 mg, about 3300 mg, and / or about 3600 mg of the anti-C5 antibody or antigen-binding fragment thereof is administered to the pediatric patient based on the patient's weight. In one embodiment, 300 mg of the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 5 kg or more and less than 10 kg. In one embodiment, 600 mg of the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 5 kg or more and less than 10 kg. In another embodiment, 600 mg of the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 10 kg or more and less than 20 kg. In another embodiment, 900 mg or 2100 mg of the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 20 kg or more and less than 30 kg. In another embodiment, 1200 mg or 2700 mg of anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 30 kg or more and less than 40 kg. In another embodiment, 2400 mg or 3000 mg of anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 40 kg or more and less than 60 kg. In another embodiment, 2700 mg or 3300 mg of anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 60 kg or more and less than 100 kg. In another embodiment, 3000 mg or 3600 mg of anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 100 kg or more. In certain embodiments, the administration regimen is adjusted to provide optimal desired remission (e.g., effective remission).
[0018] In another embodiment, the anti-C5 antibody or antigen-binding fragment thereof is administered for one or more administration cycles. In one embodiment, the administration cycle is 26 weeks. In one embodiment, the anti-C5 antibody or antigen-binding fragment thereof is administered once on day 1 of the administration cycle as a loading dose, then on day 15 of the administration cycle and every 4 weeks thereafter as a maintenance dose. In another embodiment, the anti-C5 antibody or antigen-binding fragment thereof is administered once on day 1 of the administration cycle as a loading dose, then on day 15 of the administration cycle and every 8 weeks thereafter as a maintenance dose.
[0019] In another embodiment, a method of treating a human pediatric patient with atypical hemolytic uremic syndrome (aHUS) is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody or antigen-binding fragment thereof comprising heavy chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 19, 18, and 3, respectively, and light chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 4, 5, and 6, respectively, wherein the anti-C5 antibody or antigen-binding fragment thereof is administered once on day 1 at the following doses: i. 600 mg for a patient weighing 5 kg or more and less than 10 kg; ii. 600 mg for a patient weighing 10 kg or more and less than 20 kg; iii. 900 mg for a patient weighing 20 kg or more and less than 30 kg; iv. 1200 mg for a patient weighing 30 kg or more and less than 40 kg; v. 2400 mg for a patient weighing 40 kg or more and less than 60 kg; v. and (b) on day 15, a maintenance dose of: i. 300 mg to patients weighing 5 kg to less than 10 kg, ii. 600 mg to patients weighing 10 kg to less than 20 kg, iii. 2100 mg to patients weighing 20 kg to less than 30 kg, iv. 2700 mg to patients weighing 30 kg to less than 40 kg, v. 3000 mg to patients weighing 40 kg to less than 60 kg, vi. 3300 mg to patients weighing 60 kg to less than 100 kg, or vii. 3600 mg to patients weighing 100 kg or more, with additional maintenance doses given every 4 weeks thereafter to patients weighing less than 20 kg and additional maintenance doses given every 8 weeks thereafter to patients weighing 20 kg or more.
[0020] In one embodiment, the disclosure is directed to a method of treating a human pediatric patient with atypical hemolytic uremic syndrome (aHUS), comprising administering to the patient an effective amount of an anti-C5 antibody or antigen-binding fragment thereof, comprising heavy chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 19, 18, and 3, respectively, and light chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 4, 5, and 6, respectively, and a variant human Fc constant region that binds to the human neonatal Fc receptor (FcRn), wherein the variant human Fc constant region binds to the human neonatal Fc receptor (FcRn), and the CH3 constant region comprises a Met429Leu substitution and an Asn435Ser substitution at residues corresponding to methionine 428 and asparagine 434, respectively, according to the EU numbering convention, and the anti-C5 antibody or antigen-binding fragment thereof is administered once on day 1 at a dose of: i. 600 mg for patients weighing 5 kg or more and less than 10 kg; ii. 600 mg for patients weighing 10 kg or more and less than 20 kg; iii. 900 mg for patients weighing 20 kg or more and less than 30 kg; iv. 1200 mg for patients weighing 30 kg or more and less than 40 kg; v. 2400 mg for patients weighing 40 kg or more and less than 60 kg; vi. 2700 mg for patients weighing 60 kg or more and less than 100 kg; or vii. 3000 mg for patients weighing 100 kg or more; and (b) on day 15, a maintenance dose of: i. 300 mg to patients weighing 5 kg or more and less than 10 kg, ii. 600 mg to patients weighing 10 kg or more and less than 20 kg, iii. 2100 mg to patients weighing 20 kg or more and less than 30 kg, iv. 2700 mg to patients weighing 30 kg or more and less than 40 kg, v. 3000 mg to patients weighing 40 kg or more and less than 60 kg, vi. 3300 mg to patients weighing 60 kg or more and less than 100 kg, or vii. 3600 mg to patients weighing 100 kg or more, with additional maintenance doses given every 4 weeks thereafter for patients weighing less than 20 kg, and additional maintenance doses given every 8 weeks for patients weighing 20 kg or more. In certain embodiments, the anti-C5 antibody comprises a heavy chain variable region set forth in SEQ ID NO: 12 and a light chain variable region set forth in SEQ ID NO: 8. In certain embodiments, the anti-C5 antibody further comprises a heavy chain constant region set forth in SEQ ID NO: 13.In certain embodiments, the antibody comprises a heavy chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 14 and a light chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 11. In certain embodiments, the anti-C5 antibody has an affinity dissociation constant (K) in the range of 0.1 nM to 1 nM at pH 7.4 and 25C. D In certain embodiments, the anti-C5 antibody binds to human C5 at a K DBinds to human C5 at ≧10 nM. In certain embodiments, the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen-binding fragment thereof at about 100 μg / mL or greater. In certain embodiments, the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen-binding fragment thereof at about 200 μg / mL or greater. In certain embodiments, the treatment maintains a free C5 concentration at 0.309-0.5 μg / mL or less. In certain embodiments, the anti-C5 antibody is administered at a dose of 300 mg or 600 mg every 4 weeks for up to 2 years after treatment. In certain embodiments, the anti-C5 antibody is administered at a dose of 2100 mg, 2700 mg, 3000 mg, 3300 mg, or 3600 mg every 8 weeks for up to 2 years after treatment. In certain embodiments, the anti-C5 antibody is formulated for intravenous administration. In certain embodiments, the patient has not been previously treated with a complement inhibitor. In certain embodiments, the patient is under the age of 18. In certain embodiments, the treatment is a dosing cycle comprising a total of 26 weeks of treatment. In certain embodiments, the treatment results in terminal complement inhibition. In certain embodiments, the treatment results in complete thrombotic microangiopathy (TMA) remission (normalization of platelet count, normalization of LDH, and 25% improvement from baseline in serum creatinine). In certain embodiments, the treatment results in a 25% or greater decrease in serum creatinine levels compared to baseline. In certain embodiments, the treatment results in an increase in platelet count compared to baseline. In certain embodiments, the treatment results in a decrease or cessation of at least one therapeutic marker selected from the group consisting of severe hypertension, proteinuria, uremia, malaise, fatigue, irritability, thrombocytopenia, microangiopathic hemolytic anemia, and renal dysfunction compared to baseline. In certain embodiments, the treatment shifts the level of a marker selected from the group consisting of: factor Ba, soluble tumor necrosis factor receptor 1 (sTNFR1), soluble vascular adhesion molecule 1 (sVCAM1), thrombomodulin, D-dimer, and cystatin C toward normal compared to a baseline. In certain embodiments, the treatment reduces the need for blood transfusions compared to a baseline.In certain embodiments, the treatment reduces major adverse vascular events (MAVE) compared to baseline. In certain embodiments, the treatment produces a change from baseline in quality of life as assessed via the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale, 4th edition, or the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Scale compared to baseline.
[0021] In another embodiment, lactate dehydrogenase (LDH) levels are used to assess responsiveness to treatment (e.g., a decrease in hemolysis as compared to baseline as assessed by LDH levels indicates an improvement in at least one symptom of aHUS). In one embodiment, a patient treated according to the disclosed methods experiences a decrease in LDH levels compared to baseline that is close to normal or within 10%, or within 20% (e.g., within 105-333 IU / L (international units per liter) above a value considered normal. In another embodiment, the patient's LDH levels are normalized throughout the maintenance period of treatment. In another embodiment, the treated patient's LDH levels are normalized at least at least 95% of the time during the maintenance period of treatment. In another embodiment, the treated patient's LDH levels are normalized at least at least 90%, 85%, or 80% of the time during the maintenance period of treatment. In one embodiment, the patient's LDH levels are 1.5 times or more above the upper limit of normal prior to initiation of treatment (LDH≧1.5×ULN).
[0022] In one embodiment, the disclosure is directed to a kit for treating atypical hemolytic uremic syndrome (aHUS) in a human pediatric patient, the kit comprising (a) a dose of an anti-C5 antibody or antigen-binding fragment thereof comprising CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO: 12 and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO: 8, and (b) instructions for using the anti-C5 antibody or antigen-binding fragment thereof in the method of claim 1 or 2. In a particular embodiment, the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 5 kg or more and less than 10 kg at (a) a loading dose of 600 mg once on day 1, and (b) a maintenance dose of 300 mg once on day 15 and every 4 weeks thereafter. In certain embodiments, the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 10 kg or more and less than 20 kg (a) once on day 1 with a loading dose of 600 mg, and (b) once on day 15 and every 4 weeks with a maintenance dose of 600 mg thereafter. In certain embodiments, the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 20 kg or more and less than 30 kg (a) once on day 1 with a loading dose of 900 mg, and (b) once on day 15 and every 8 weeks with a maintenance dose of 2100 mg thereafter. In certain embodiments, the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 30 kg or more and less than 40 kg (a) once on day 1 with a loading dose of 1200 mg, and (b) once on day 15 and every 8 weeks with a maintenance dose of 2700 mg thereafter. In certain embodiments, the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 40 kg or more and less than 60 kg (a) once on day 1 with a loading dose of 2400 mg, and (b) once on day 15 and every 8 weeks with a maintenance dose of 3000 mg thereafter. In certain embodiments, the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 60 kg or more and less than 100 kg (a) once on day 1 with a loading dose of 2700 mg, and (b) once on day 15 and every 8 weeks with a maintenance dose of 3300 mg thereafter.In a specific embodiment, the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 100 kg or more at (a) a loading dose of 3000 mg once on day 1, and (b) a maintenance dose of 3600 mg once on day 15 and every 8 weeks thereafter.
[0023] In one embodiment, the disclosure is directed to an anti-C5 antibody or antigen-binding fragment thereof comprising a CDR1 domain, a CDR2 domain, and a CDR3 domain of a heavy chain variable region having the sequence set forth in SEQ ID NO: 12, and a CDR1 domain, a CDR2 domain, and a CDR3 domain of a light chain variable region having the sequence set forth in SEQ ID NO: 8, the anti-C5 antibody or antigen-binding fragment thereof being administered once on day 1, i. 600 mg for a patient weighing 5 kg or more and less than 10 kg, ii. 600 mg for a patient weighing 10 kg or more and less than 20 kg, iii. 900 mg for a patient weighing 20 kg or more and less than 30 kg, iv. 1200 mg for a patient weighing 30 kg or more and less than 40 kg, v. 2400 mg for a patient weighing 40 kg or more and less than 60 kg, and vi. and (b) on day 15, a maintenance dose of: i. 300 mg to patients weighing 5 kg or more but less than 10 kg, ii. 600 mg to patients weighing 10 kg or more but less than 20 kg, iii. 2100 mg to patients weighing 20 kg or more but less than 30 kg, iv. 2700 mg to patients weighing 30 kg or more but less than 40 kg, v. 3000 mg to patients weighing 40 kg or more but less than 60 kg, vi. 3300 mg to patients weighing 60 kg or more but less than 100 kg, or vii. 3600 mg to patients weighing 100 kg or more, with additional maintenance doses given every 4 weeks thereafter to patients weighing less than 20 kg and additional maintenance doses given every 8 weeks thereafter to patients weighing 20 kg or more. In certain embodiments, the antibody is determined to be safe, tolerated, effective, and sufficiently non-immunogenic after multiple IV administrations in aHUS patients.
[0024] In another embodiment, the anti-C5 antibody is administered on a monthly basis (e.g., every 4 weeks) or on a bimonthly basis (e.g., every 8 weeks) after completion of the treatment (e.g., administration cycle). In another embodiment, the anti-C5 antibody or antigen-binding fragment thereof is administered on a monthly or bimonthly basis for one year after completion of the treatment (e.g., administration cycle). In another embodiment, the anti-C5 antibody or antigen-binding fragment thereof is administered on a monthly or bimonthly basis for two, three, four or five years after completion of the treatment (e.g., administration cycle). In a particular embodiment, the anti-C5 antibody or antigen-binding fragment thereof is administered on a monthly or bimonthly basis for up to two years after completion of the treatment (e.g., administration cycle).
[0025] In another aspect, the described treatment regimen is sufficient to maintain a particular serum trough concentration of the anti-C5 antibody or antigen-binding fragment thereof. In one embodiment, the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen-binding fragment thereof at or above 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 200, 205, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810 In one embodiment, the treatment maintains serum trough concentrations of an anti-C5 antibody or antigen-binding fragment thereof at or above 10, 215, 220, 225, 230, 240, 245, 250, 255, 260, 265, 270, 280, 290, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, or 400 μg / mL. In one embodiment, the treatment maintains serum trough concentrations of an anti-C5 antibody or antigen-binding fragment thereof at or above 100 μg / mL, 150 μg / mL, 200 μg / mL, 250 μg / mL, or 300 μg / mL. In another embodiment, the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen-binding fragment thereof between 100 μg / mL and 200 μg / mL, hi another embodiment, the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen-binding fragment thereof at about 175 μg / mL.
[0026] In another embodiment, to achieve effective remission, the anti-C5 antibody is administered at least 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 105 μg, 110 μg, 115 μg, 120 μg, 125 μg, 130 μg, 135 μg, 140 μg, 145 μg, 150 μg, 160 μg, 170 μg, 175 μg, 180 μg, 185 μg, 190 μg, 200 μg, 210 μg, 220 μg, 230 μg, 240 μg, 250 μg, 260 μg, 270 μg, 280 μg, 290 μg, 300 μg, 310 μg, 320 μg, 330 μg, 340 μg, 350 μg, 360 μg, 370 μg, 380 μg, 390 μg, 400 μg, 410 μg, 420 μg, 430 μg, 440 μg, 450 μg, 460 μg, 470 μg, 480 μg, 490 μg, 500 μg, 510 μg, 520 μg, 530 μg, 540 μg, 550 μg, 560 μg, 570 μg, 580 μg, 590 μg, 600 μg, 610 μg, 620 μg, 630 μg, 640 In another embodiment, the anti-C5 antibody is administered to the patient in an amount and frequency to maintain between 0 μg, 155 μg, 160 μg, 165 μg, 170 μg, 175 μg, 180 μg, 185 μg, 190 μg, 195 μg, 200 μg, 205 μg, 210 μg, 215 μg, 220 μg, 225 μg, 230 μg, 235 μg, 240 μg, 245 μg, 250 μg, 255 μg, or 260 μg of antibody per milliliter of blood of the patient. In another embodiment, the anti-C5 antibody is administered to the patient in an amount and frequency to maintain between 50 μg and 250 μg of antibody per milliliter of blood of the patient. In another embodiment, the anti-C5 antibody is administered to the patient in an amount and frequency to maintain between 100 μg and 200 μg of antibody per milliliter of blood of the patient. In another embodiment, the anti-C5 antibody is administered to the patient in an amount and frequency to maintain the patient at about 175 μg of antibody per milliliter of blood.
[0027] In another embodiment, the anti-C5 antibody is administered to the patient in an amount and frequency to maintain a minimum free C5 concentration to obtain effective remission. In one embodiment, for example, the anti-C5 antibody is administered to the patient in an amount and frequency to maintain a free C5 concentration of 0.5 μg / mL, 0.4 μg / mL, 0.3 μg / mL, 0.2 μg / mL or less. In one embodiment, the anti-C5 antibody is administered to the patient in an amount and frequency to maintain a free C5 concentration of 0.309 to 0.5 μg / mL.
[0028] In another embodiment, the treatment results in a complete thrombotic microangiopathy (TMA) response. In another embodiment, the treatment results in a complete thrombotic microangiopathy remission (cTMA) that is maintained for more than 170 days (e.g., more than 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182 days 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 205, 210, 215, 220, or 225 days) after initiation of treatment.
[0029] In another embodiment, the treatment results in a decrease in serum creatinine levels compared to baseline, hi certain embodiments, the treatment results in a 25% or greater decrease in serum creatinine levels compared to baseline.
[0030] In another embodiment, the treatment eliminates the need for the patient to undergo dialysis, hi another embodiment, the patient stops dialysis within 35 days (e.g., 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, or 10 days) of starting treatment.
[0031] In certain embodiments, the treatment produces a change from baseline in quality of life as assessed via the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale, 4th edition, and the European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30 Scale. In one embodiment, the treatment produces a change from baseline in quality of life of 1 or more points (e.g., 1, 2, or 3) as assessed via the FACIT-Fatigue scale. In another embodiment, treatment is associated with a 3 point change from baseline in quality of life as assessed via the FACIT-Fatigue scale for 150 days or more (e.g., 150 days, 151 days, 152 days, 153 days, 154 days, 155 days, 156 days, 157 days, 158 days, 159 days, 160 days, 161 days, 162 days, 163 days, 164 days, 165 days, 166 days, 167 days, 168 days, 169 days, 170 days, or more) after initiation of treatment. , 171 days, 172 days, 173 days, 174 days, 175 days, 176 days, 177 days, 178 days, 179 days, 180 days, 181 days, 182 days, 183 days, 184 days, 185 days, 186 days, 187 days, 188 days, 189 days, 190 days, 191 days, 192 days, 193 days, 194 days, 195 days, 196 days, 197 days, 198 days, 199 days, 200 days, 205 days, 210 days, 215 days, 220 days or 225 days).
[0032] In another embodiment, the patient's chronic kidney disease (CKD) improves by one or more stages (e.g., 1, 2, 3, 4, or 5 stages) after initiation of treatment. In another embodiment, the patient's CKD ...50 days, 151 days, 152 days, 153 days, 154 days, 155 days, 156 days, 157 days, 158 days, 159 days, 160 days, 161 days, 162 days, 163 days, 164 days, 165 days, 166 days, 167 days, 168 days, 169 days, 170 days, 171 days, 172 days, 173 days, 174 days, 175 days, 176 days, or 177 days) after initiation of treatment. days, 177 days, 178 days, 179 days, 180 days, 181 days, 182 days, 183 days, 184 days, 185 days, 186 days, 187 days, 188 days, 189 days, 190 days, 191 days, 192 days, 193 days, 194 days, 195 days, 196 days, 197 days, 198 days, 199 days, 200 days, 205 days, 210 days, 215 days, 220 days or 225 days), improving by one or more stages. The present invention provides, for example, the following items. (Item 1) 1. A method of treating a human pediatric patient with atypical hemolytic uremic syndrome (aHUS), comprising administering to the patient an effective amount of an anti-C5 antibody or antigen-binding fragment thereof comprising heavy chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 19, 18, and 3, respectively, and light chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 4, 5, and 6, respectively, wherein the anti-C5 antibody or antigen-binding fragment thereof is (a) On Day 1, i. 600 mg for patients weighing 5 kg or more but less than 10 kg ii. 600 mg for patients weighing 10 kg or more but less than 20 kg; iii. 900 mg for patients weighing 20 kg or more but less than 30 kg; iv. 1200 mg for patients weighing 30 kg or more but less than 40 kg; v. 2,400 mg for patients weighing 40 kg or more but less than 60 kg; vi. 2700 mg for patients weighing 60 kg or more but less than 100 kg; or vii. A single loading dose of 3,000 mg for patients weighing 100 kg or more; and (b) On the 15th day, i. 300 mg for patients weighing 5 kg or more but less than 10 kg ii. 600 mg for patients weighing 10 kg or more but less than 20 kg; iii. 2100 mg for patients weighing 20 kg or more but less than 30 kg; iv. 2700 mg for patients weighing 30 kg or more but less than 40 kg; v. 3,000 mg for patients weighing 40 kg or more but less than 60 kg; vi. 3,300 mg for patients weighing 60 kg or more but less than 100 kg; or vii. A maintenance dose of 3600 mg is administered to patients weighing 100 kg or more. Patients weighing less than 20 kg are given additional maintenance doses every 4 weeks thereafter, and patients weighing 20 kg or more are given additional maintenance doses every 8 weeks thereafter. (Item 2) 1. A method of treating a human pediatric patient with atypical hemolytic uremic syndrome (aHUS), comprising administering to the patient an effective amount of an anti-C5 antibody or antigen-binding fragment thereof comprising heavy chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 19, 18, and 3, respectively, light chain sequences of CDR1, CDR2, and CDR3 set forth in SEQ ID NOs: 4, 5, and 6, respectively, and a variant human Fc constant region that binds to a human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises substitutions of Met429Leu and Asn435Ser at residues corresponding to methionine 428 and asparagine 434, respectively, according to the EU numbering convention, and wherein the anti-C5 antibody or antigen-binding fragment thereof is (a) On Day 1, i. 600 mg for patients weighing 5 kg or more but less than 10 kg ii. 600 mg for patients weighing 10 kg or more but less than 20 kg; iii. 900 mg for patients weighing 20 kg or more but less than 30 kg; iv. 1200 mg for patients weighing 30 kg or more but less than 40 kg; v. 2,400 mg for patients weighing 40 kg or more but less than 60 kg; vi. 2700 mg for patients weighing 60 kg or more but less than 100 kg; or vii. A single loading dose of 3,000 mg for patients weighing 100 kg or more; and (b) On the 15th day, i. 300 mg for patients weighing 5 kg or more but less than 10 kg ii. 600 mg for patients weighing 10 kg or more but less than 20 kg; iii. 2100 mg for patients weighing 20 kg or more but less than 30 kg; iv. 2700 mg for patients weighing 30 kg or more but less than 40 kg; v. 3,000 mg for patients weighing 40 kg or more but less than 60 kg; vi. 3,300 mg for patients weighing 60 kg or more but less than 100 kg; or vii. A maintenance dose of 3600 mg is administered to patients weighing 100 kg or more. Patients weighing less than 20 kg are given additional maintenance doses every 4 weeks thereafter, and patients weighing 20 kg or more are given additional maintenance doses every 8 weeks thereafter. (Item 3) 3. The method of claim 1 or 2, wherein the anti-C5 antibody comprises a heavy chain variable region set forth in SEQ ID NO: 12 and a light chain variable region set forth in SEQ ID NO: 8. (Item 4) 4. The method according to any one of items 1 to 3, wherein the anti-C5 antibody further comprises a heavy chain constant region set forth in SEQ ID NO:13. (Item 5) 5. The method according to any one of items 1 to 4, wherein the antibody comprises a heavy chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 14 and a light chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 11. (Item 6) The anti-C5 antibody has an affinity dissociation constant (K) in the range of 0.1 nM to 1 nM at pH 7.4 and 25°C. D 6. The method according to any one of items 1 to 5, wherein the antibody binds to human C5 via the antibody binding domain. (Item 7) The anti-C5 antibody is D 7. The method of any one of items 1 to 6, wherein the antibody binds to human C5 at ≧10 nM at pH 6.0 and 25C. (Item 8) The anti-C5 antibody is administered to a patient weighing 5 kg or more and less than 10 kg, (a) administered once on day 1 as a loading dose of 600 mg; and (b) A maintenance dose of 300 mg administered once on day 15, and every 4 weeks thereafter. (Item 9) The anti-C5 antibody is administered to a patient weighing 10 kg or more and less than 20 kg, (a) administered once on day 1 as a loading dose of 600 mg; and (b) A maintenance dose of 600 mg administered once on day 15, and every 4 weeks thereafter. (Item 10) The anti-C5 antibody is administered to a patient weighing 20 kg or more and less than 30 kg, (a) administered once on day 1 as a loading dose of 900 mg; and (b) A method according to any one of items 1 to 7, administered at a maintenance dose of 2100 mg once on day 15, and every 8 weeks thereafter. (Item 11) The anti-C5 antibody is administered to a patient weighing 30 kg or more and less than 40 kg, (a) administered once on day 1 as a loading dose of 1,200 mg; and (b) A method according to any one of items 1 to 7, administered at a maintenance dose of 2700 mg once on day 15, and every 8 weeks thereafter. (Item 12) The anti-C5 antibody is administered to a patient weighing 40 kg or more and less than 60 kg, (a) administered once on day 1 as a loading dose of 2400 mg; and (b) A maintenance dose of 3000 mg administered once on day 15, and every 8 weeks thereafter. (Item 13) The anti-C5 antibody is administered to a patient weighing 60 kg or more and less than 100 kg, (a) administered once on day 1 as a loading dose of 2700 mg; and (b) A method according to any one of items 1 to 7, administered at a maintenance dose of 3300 mg once on day 15, and every 8 weeks thereafter. (Item 14) The anti-C5 antibody is administered to a patient weighing 100 kg or more. (a) administered once on day 1 as a loading dose of 3,000 mg; and (b) A method according to any one of items 1 to 7, administered at a maintenance dose of 3600 mg once on day 15, and every 8 weeks thereafter. (Item 15) 15. The method according to any one of items 1 to 14, wherein the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen-binding fragment thereof at 100 μg / mL or greater. (Item 16) 16. The method according to any one of items 1 to 15, wherein the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen-binding fragment thereof at 200 μg / mL or greater. (Item 17) 17. The method according to any one of items 1 to 16, wherein the treatment maintains a free C5 concentration of 0.309 to 0.5 μg / mL or less. (Item 18) 18. The method of any one of items 1 to 17, wherein the anti-C5 antibody is administered at a dose of 300 mg or 600 mg every 4 weeks for up to 2 years after treatment. (Item 19) 19. The method of any one of items 1 to 18, wherein the anti-C5 antibody is administered at a dose of 2100 mg, 2700 mg, 3000 mg, 3300 mg, or 3600 mg every 8 weeks for up to 2 years after treatment. (Item 20) 20. The method of any one of items 1 to 19, wherein the anti-C5 antibody is formulated for intravenous administration. (Item 21) 21. The method of any one of items 1 to 20, wherein the patient has not been previously treated with a complement inhibitor. (Item 22) 22. The method according to any one of items 1 to 21, wherein the patient is under 18 years of age. (Item 23) 23. The method according to any one of items 1 to 22, wherein the treatment is a dosing cycle comprising a total of 26 weeks of treatment. (Item 24) 24. The method according to any one of items 1 to 23, wherein the treatment results in terminal complement inhibition. (Item 25) 25. The method of any one of items 1 to 24, wherein the treatment results in a complete thrombotic microangiopathy (TMA) response. (Item 26) 26. The method of any one of items 1 to 25, wherein the treatment results in a 25% or greater decrease in serum creatinine level compared to baseline. (Item 27) 27. The method according to any one of items 1 to 26, wherein the treatment results in an increase in platelet count compared to a baseline. (Item 28) 28. The method of any one of items 1 to 27, wherein the treatment results in a decrease in hemolysis compared to a baseline as assessed by lactate dehydrogenase (LDH) levels. (Item 29) 3. The method of claim 1 or 2, wherein said treatment results in a reduction or cessation of at least one therapeutic marker selected from the group consisting of severe hypertension, proteinuria, uremia, malaise, fatigue, irritability, thrombocytopenia, microangiopathic hemolytic anemia and renal dysfunction compared to baseline. (Item 30) 30. The method of any one of items 1 to 29, wherein the treatment results in a shift to normal levels of a marker selected from the group consisting of factor Ba, soluble tumor necrosis factor receptor 1 (sTNFR1), soluble vascular adhesion molecule 1 (sVCAM1), thrombomodulin, D-dimer, and cystatin C, compared to the reference. (Item 31) 31. The method of any one of items 1 to 30, wherein the treatment results in a reduction in the need for blood transfusions compared to a baseline. (Item 32) 32. The method of any one of items 1 to 31, wherein the treatment results in a reduction in major adverse vascular events (MAVE) compared to a baseline. (Item 33) 33. The method of any one of items 1 to 32, wherein the treatment produces a change from baseline in quality of life assessed via the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale, 4th edition, or the European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30 Scale, compared to baseline. (Item 34) 1. A kit for treating atypical hemolytic uremic syndrome (aHUS) in a human pediatric patient, comprising: (a) a dose of an anti-C5 antibody or antigen-binding fragment thereof, comprising CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO: 12 and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO: 8; and (b) A kit according to the method of item 1 or 2, comprising instructions for using the anti-C5 antibody or antigen-binding fragment thereof. (Item 35) The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 5 kg or more and less than 10 kg. (a) administered once on day 1 as a loading dose of 600 mg; and (b) The kit according to item 34, administered at a maintenance dose of 300 mg once on day 15, and every 4 weeks thereafter. (Item 36) The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 10 kg or more and less than 20 kg. (a) administered once on day 1 as a loading dose of 600 mg; and (b) The kit according to item 34, administered at a maintenance dose of 600 mg once on day 15, and every 4 weeks thereafter. (Item 37) The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 20 kg or more and less than 30 kg. (a) administered once on day 1 as a loading dose of 900 mg; and (b) The kit according to item 34, administered at a maintenance dose of 2100 mg once on day 15, and every 8 weeks thereafter. (Item 38) The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 30 kg or more and less than 40 kg. (a) administered once on day 1 as a loading dose of 1,200 mg; and (b) The kit according to item 34, administered at a maintenance dose of 2700 mg once on day 15, and every 8 weeks thereafter. (Item 39) The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 40 kg or more and less than 60 kg. (a) administered once on day 1 as a loading dose of 2400 mg; and (b) The kit according to item 34, administered at a maintenance dose of 3000 mg once on day 15, and every 8 weeks thereafter. (Item 40) The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 60 kg or more and less than 100 kg. (a) administered once on day 1 as a loading dose of 2700 mg; and (b) The kit according to item 34, administered at a maintenance dose of 3300 mg once on day 15, and every 8 weeks thereafter. (Item 41) The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 100 kg or more. (a) administered once on day 1 as a loading dose of 3,000 mg; and (b) The kit according to item 34, administered at a maintenance dose of 3600 mg once on day 15, and every 8 weeks thereafter. (Item 42) An anti-C5 antibody or antigen-binding fragment thereof, comprising CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO: 12, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO: 8, wherein the anti-C5 antibody or antigen-binding fragment thereof is (a) On Day 1, i. 600 mg for patients weighing 5 kg or more but less than 10 kg ii. 600 mg for patients weighing 10 kg or more but less than 20 kg; iii. 900 mg for patients weighing 20 kg or more but less than 30 kg; iv. 1200 mg for patients weighing 30 kg or more but less than 40 kg; v. 2,400 mg for patients weighing 40 kg or more but less than 60 kg; vi. 2700 mg for patients weighing 60 kg or more but less than 100 kg; or vii. A single loading dose of 3,000 mg for patients weighing 100 kg or more; and (b) On the 15th day, i. 300 mg for patients weighing 5 kg or more but less than 10 kg ii. 600 mg for patients weighing 10 kg or more but less than 20 kg; iii. 2100 mg for patients weighing 20 kg or more but less than 30 kg; iv. 2700 mg for patients weighing 30 kg or more but less than 40 kg; v. 3,000 mg for patients weighing 40 kg or more but less than 60 kg; vi. 3,300 mg for patients weighing 60 kg or more but less than 100 kg; or vii. A maintenance dose of 3600 mg is administered to patients weighing 100 kg or more. Patients weighing less than 20 kg are given additional maintenance doses every 4 weeks thereafter, and patients weighing 20 kg or more are given additional maintenance doses every 8 weeks thereafter, an anti-C5 antibody or antigen-binding fragment thereof. (Item 43) 43. The antibody of claim 42, wherein the antibody is determined to be safe, tolerable, effective, and sufficiently non-immunogenic after multiple IV administrations in aHUS patients. [Brief description of the drawings]
[0033] [Figure 1] FIG. 1 is a schematic showing the dosing regimen study design. [Diagram 2]FIG. 2 is a schematic diagram showing patient positioning. [Diagram 3] FIG. 3 is a graph showing major complete thrombotic microangiopathy (cTMA) remission. [Figure 4] FIG. 4 is a Venn diagram showing major cTMA remissions. [Diagram 5] FIG. 5 is a graph showing time to cTMA remission. [Figure 6] FIG. 6 is a graph showing the status of components of cTMA remission, hematological normalization, and cTMA remission status over time. [Figure 7] FIG. 7 shows the observed and model-based platelet changes over time during the initial evaluation period (full analysis set). [Figure 8] FIG. 8 is a graph showing observed and model-based changes in LDH over time during the initial evaluation period (full analysis set). [Figure 9] Figure 9 shows a graph of observed and model-based hemoglobin changes over time during the initial evaluation period (full analysis set). [Figure 10] FIG. 10 shows dialysis status or events by patient within 5 days of starting treatment or over time after first dose in patients who were on dialysis (full analysis set). [Figure 11] FIG. 11 is a graph showing the measured and model-based values over time. [Figure 12] Figure 12 shows measured and model-based changes in children's FACIT fatigue over time (full analysis set). [Figure 13] Figure 13 is a graph showing the mean (SD) of ravulizumab serum concentrations by dosing interval (Q4W and Q8W). Linear scale (PK / PD analysis population). [Figure 14] FIG. 14 is a graph showing the time profile of serum free C5 concentrations by dosing interval (Q4W and Q8W) (PK / PD analysis population). [Figure 15]FIG. 15 is a graph showing the time profile of mean total serum concentrations (95% CI) by dosing interval (Q4W and Q8W) (PK / PD analysis population). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] I. Definition As used herein, the term "subject" or "patient" refers to a human patient (e.g., a pediatric patient with aHUS).
[0035] As used herein, "effective treatment" refers to treatment that produces a beneficial effect, such as an improvement in at least one symptom of a disease or disorder. The beneficial effect may be in the form of an improvement over a baseline, i.e., an improvement over a measurement or observation made prior to initiating therapy according to the subject methods. Effective treatment may refer to a reduction in at least one symptom of aHUS, such as severe hypertension, proteinuria, uremia, fatigue / fatigue, irritability, thrombocytopenia, microangiopathic hemolytic anemia, and renal dysfunction (e.g., acute renal failure).
[0036] The term "effective amount" refers to an amount of an agent that produces a desired biological, therapeutic, and / or prophylactic result. The result may be a reduction, amelioration, alleviation, attenuation, delay, and / or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired change in a biological system. In one example, an "effective amount" is an amount of an anti-C5 antibody or antigen-binding fragment thereof that has been clinically proven to reduce at least one symptom of aHUS (e.g., severe hypertension, proteinuria, uremia, fatigue / fatigue, irritability, thrombocytopenia, microangiopathic hemolytic anemia, and renal dysfunction (e.g., acute renal failure)). An "effective amount" can be administered in one or more doses.
[0037] As used herein, the terms "induction" and "induction phase" are used interchangeably and refer to Phase I of treatment in a clinical trial setting or as part of a patient's treatment regimen.
[0038] As used herein, the terms "maintenance" and "maintenance phase" are used interchangeably and refer to Phase II of treatment in a clinical trial setting or as part of a patient's treatment regimen. In certain embodiments, treatment is continued as long as clinical benefit is observed or until unmanageable toxicity or disease progression occurs.
[0039] As used herein, the term "serum trough level" refers to the lowest level at which an agent (e.g., an anti-C5 antibody or an antigen-binding fragment thereof) or drug is present in serum. In contrast, "peak serum level" refers to the highest level of an agent in serum. "Average serum level" refers to the average level of an agent in serum over time.
[0040] The term "antibody" refers to a polypeptide comprising at least one antigen-binding site (e.g., VH / VL regions or Fv or CDRs) from an antibody. Antibodies include known antibody types, for example, an antibody may be a human antibody, a humanized antibody, a bispecific antibody, or a chimeric antibody. An antibody may also be a Fab, Fab'2, ScFv, SMIP, Affibody®, nanobody, or single domain antibody. An antibody may further be any of the following isotypes: IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE, or a combination thereof. An antibody may be a naturally occurring antibody or an antibody that has been altered by protein engineering techniques (e.g., mutation, deletion, substitution, conjugation with a non-antibody moiety, etc.). An antibody may comprise one or more variant amino acids (compared to a naturally occurring antibody) that, for example, alters the properties (e.g., functional properties) of the antibody. Many such modifications are known in the art that affect, for example, the half-life, effector functions, and / or immune response to the antibody in a patient. The term antibody also includes artificial or modified polypeptide constructs that contain at least one antigen-binding site derived from an antibody.
[0041] II. Anti-C5 antibody The anti-C5 antibodies described herein bind to complement component C5 (e.g., human C5) and inhibit cleavage of C5 into the fragments C5a and C5b. As described above, the antibodies also have improved pharmacokinetic properties compared to, for example, other anti-C5 antibodies used for therapeutic purposes (e.g., eculizumab).
[0042] Anti-C5 antibodies (or VH / VL domains derived therefrom) suitable for use in the methods described herein can be generated using methods known in the art. Alternatively, art-recognized anti-C5 antibodies can be used. Antibodies that compete with any of these art-recognized antibodies or those described herein for binding to C5 can also be used.
[0043] An example of an anti-C5 antibody is ravulizumab, or an antigen-binding fragment thereof and variants thereof, containing heavy and light chains having the sequences shown in SEQ ID NOs: 14 and 11, respectively. Rabulizumab (also known as BNJ441 and ALXN1210) is described in International Patent Application No. PCT / US2015 / 019225 and U.S. Patent No. 9,079,949, the entire teachings of which are incorporated herein by reference. The terms ravulizumab, BNJ441 and ALXN1210 may be used interchangeably throughout this document, but all refer to the same antibody. Rabulizumab selectively binds to the human complement protein C5 and inhibits cleavage of C5 into C5a and C5b during complement activation. This inhibition prevents the release of the proinflammatory mediator C5a and the formation of the cytolytic pore-forming membrane attack complex (MAC) C5b-9, while preserving the proximal or early components of complement activation (e.g., C3 and C3b), which are essential for microbial opsonization and immune complex clearance.
[0044] In other embodiments, the antibody comprises the heavy and light chain CDRs or variable regions of ravulizumab. Thus, in one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of ravulizumab having the sequence set forth in SEQ ID NO: 12, and the CDR1, CDR2, and CDR3 domains of the VL region of ravulizumab having the sequence set forth in SEQ ID NO: 8. In another embodiment, the antibody comprises the heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18, and 3, respectively, and the light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively. In another embodiment, the antibody comprises the VH and VL regions having the amino acid sequences set forth in SEQ ID NOs: 12 and 8, respectively.
[0045] Another exemplary anti-C5 antibody is antibody BNJ421, or antigen-binding fragments and variants thereof, comprising heavy and light chains having the sequences set forth in SEQ ID NOs: 20 and 11, respectively. BNJ421 (also known as ALXN1211) is described in International Patent Application No. PCT / US2015 / 019225 and U.S. Patent No. 9,079,949, the entire teachings of which are incorporated herein by reference.
[0046] In other embodiments, the antibody comprises the heavy and light chain CDRs or variable regions of BNJ421. Thus, in one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of BNJ421 having the sequence set forth in SEQ ID NO: 12, and the CDR1, CDR2, and CDR3 domains of the VL region of BNJ421 having the sequence set forth in SEQ ID NO: 8. In another embodiment, the antibody comprises the heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NO: 19, 18, and 3, respectively, and the light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NO: 4, 5, and 6, respectively. In another embodiment, the antibody comprises the VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO: 8, respectively.
[0047] The exact boundaries of the CDRs are defined differently according to different methods. In some embodiments, the locations of the CDRs or framework regions in a light chain variable domain or a heavy chain variable domain are as defined in Kabat et al. [(1991) "Sequences of Proteins of Immunological Interest." NIH Publication No. 91-3242, USDepartment of Health and Human Services, Bethesda, MD]. In such cases, the CDRs may be referred to as "Kabat CDRs" (e.g., "Kabat LCDR2" or "Kabat HCDR1"). In some embodiments, the locations of the CDRs in a light chain variable region or a heavy chain variable region are as defined by Chothia et al. (Nature, 342:877-83, 1989). Thus, these regions may be referred to as "Chothia CDRs" (e.g., "Chothia LCDR2" or "Chothia HCDR3"). In some embodiments, the positions of the CDRs of the light chain variable region and the heavy chain variable region may be defined by a combined Kabat and Chothia (Kabat-Chothia) definition. In such embodiments, these regions may be referred to as "Kabat-Chothia combination CDRs." Thomas, C. et al. (Mol. Immunol., 33:1389-401, 1996) provides examples of identifying CDR boundaries according to the Kabat and Chothia numbering scheme.
[0048] Another exemplary anti-C5 antibody is the 7086 antibody described in U.S. Patent Nos. 8,241,628 and 8,883,158. In one embodiment, the antibody comprises the heavy and light chain CDRs or variable regions of the 7086 antibody (see U.S. Patent Nos. 8,241,628 and 8,883,158). In another embodiment, the antibody or antigen-binding fragment thereof comprises heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 21, 22, and 23, respectively, and light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 24, 25, and 26, respectively. In another embodiment, the antibody or antigen-binding fragment thereof comprises the VH region of the 7086 antibody having the sequence set forth in SEQ ID NO: 27, and the VL region of the 7086 antibody having the sequence set forth in SEQ ID NO: 28.
[0049] Another exemplary anti-C5 antibody is the 8110 antibody, further described in U.S. Patent Nos. 8,241,628 and 8,883,158. In one embodiment, the antibody comprises the heavy and light chain CDRs or variable regions of the 8110 antibody. In another embodiment, the antibody or antigen-binding fragment thereof comprises heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs:29, 30, and 31, respectively, and light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs:32, 33, and 34, respectively. In another embodiment, the antibody comprises the VH region of the 8110 antibody having the sequence set forth in SEQ ID NO:35, and the VL region of the 8110 antibody having the sequence set forth in SEQ ID NO:36.
[0050] Another exemplary anti-C5 antibody is the 305LO5 antibody described in US Patent US2016 / 0176954A1. In one embodiment, the antibody comprises the heavy and light chain CDRs or variable regions of the 305LO5 antibody. In another embodiment, the antibody or antigen-binding fragment thereof comprises heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 37, 38, and 39, respectively, and light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 40, 41, and 42, respectively. In another embodiment, the antibody comprises the VH region of the 305LO5 antibody having the sequence set forth in SEQ ID NO: 43, and the VL region of the 305LO5 antibody having the sequence set forth in SEQ ID NO: 44.
[0051] Another exemplary anti-C5 antibody is the SKY59 antibody (Fukuzawa, T. et al., Sci. Rep., 7:1080, 2017). In one embodiment, the antibody comprises the heavy and light chain CDRs or variable regions of the SKY59 antibody. In another embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain comprising SEQ ID NO:45 and a light chain comprising SEQ ID NO:46.
[0052] In some embodiments, the anti-C5 antibodies described herein comprise a heavy chain CDR1 comprising or consisting of the following amino acid sequence: GHIFSNYWIQ (SEQ ID NO: 19). In some embodiments, the anti-C5 antibodies described herein comprise a heavy chain CDR2 comprising or consisting of the following amino acid sequence: EILPGSGHTEYTENFKD (SEQ ID NO: 18). In some embodiments, the anti-C5 antibodies described herein comprise a heavy chain variable region comprising the following amino acid sequence: QVQLVQSGAEVKKPGASVKV SCKASGHIFS NYWIQWVRQA PGQGLEWMGE ILPGSGHTEYTENFKDRVTM TRDTSTSTVY MELSSLRSEDTAVYYCARYF FGSSPNWYFD VWGQGTLVTV SS (Sequence number 12).
[0053] In some embodiments, the anti-C5 antibodies described herein comprise a light chain variable region comprising the following amino acid sequence: DIQMTQSPSSLSASVGDRVT ITCGASENIY GALNWYQQKP GKAPKLLIYGATNLADGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQNVLNTPLTFGQ GTKVEIK (sequence number 8).
[0054] In some embodiments, the anti-C5 antibodies described herein can comprise a variant human Fc constant region that binds to the human neonatal Fc receptor (FcRn) with higher affinity than that of the native human Fc constant region from which the variant human Fc constant region is derived. For example, the Fc constant region can comprise one or more (e.g., 2, 3, 4, 5, 6, 7, or 8 or more) amino acid substitutions compared to the native human Fc constant region from which the variant human Fc constant region is derived. The substitutions can increase the binding affinity of an IgG antibody containing the variant Fc constant region to FcRn at pH 6.0 while maintaining the pH-dependence of the interaction. Methods for testing whether one or more substitutions in the Fc constant region of an antibody increase the affinity of the Fc constant region to FcRn at pH 6.0 (while maintaining the pH-dependence of the interaction) are known in the art and are illustrated in the Examples. See, e.g., International Patent Application No. PCT / US2015 / 019225 and U.S. Patent No. 9,079,949, the disclosures of each of which are incorporated by reference in their entireties.
[0055] Substitutions that increase the binding affinity of an antibody Fc constant region to FcRn are known in the art, and include, for example, (1) triple substitutions of M252Y / S254T / T256E (Dall'Acqua, W. et al., J. Biol. Chem., 281:23514-24, 2006), (2) substitutions of M428L or T250Q / M428L (Hinton, P. et al., J. Biol. Chem., 281:23514-24, 2006), and (3) substitutions of M428L or T250Q / M428L (Hinton, P. et al., J. Biol. Chem., 281:23514-24, 2006). 279:6213-6, 2004; Hinton, P. et al., J. Immunol., 176:346-56, 2006), and (3) N434A or T307 / E380A / N434A substitutions (Petkova, S. et al., Int. Immunol., 18:1759-69, 2006)., 18:1759-69, 2006). Additional substitution combinations include P257I / Q311I, P257I / N434H, and D376V / N434H (Datta-Mannan, A. et al., J. Biol. Chem., 282:1709-17, 2007), the disclosures of each of which are incorporated herein by reference in their entirety.
[0056] In some embodiments, the variant constant region has a substitution at EU amino acid position 255 for valine. In some embodiments, the variant constant region has a substitution at EU amino acid position 309 for asparagine. In some embodiments, the variant constant region has a substitution at EU amino acid position 312 for isoleucine. In some embodiments, the variant constant region has a substitution at EU amino acid position 386.
[0057] In some embodiments, the variant Fc constant region comprises 30 or fewer (e.g., 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2) amino acid substitutions, insertions, or deletions relative to the native constant region from which it is derived. In some embodiments, the variant Fc constant region comprises one or more amino acid substitutions selected from the group consisting of: M252Y, S254T, T256E, N434S, M428L, V259I, T250I, and V308F. In some embodiments, the variant human Fc constant region comprises a methionine at position 428 and an asparagine at position 434 of the native human IgG Fc constant region, each according to EU numbering. In some embodiments, the variant Fc constant region comprises two substitutions, 428L / 434S, e.g., as described in U.S. Pat. No. 8,088,376.
[0058] In some embodiments, the exact positions of these mutations may be shifted from the natural human Fc constant region positions by antibody engineering. For example, when used in an IgG2 / 4 chimeric Fc, the two substitutions 428L / 434S may correspond to 429L and 435S, as in the M429L and N435S variants found in ravulizumab and described in U.S. Patent No. 9,079,949, which is incorporated herein by reference in its entirety.
[0059] In some embodiments, the variant constant region comprises a substitution at amino acid position 237, 238, 239, 248, 250, 252, 254, 255, 256, 257, 258, 265, 270, 286, 289, 297, 298, 303, 305, 307, 308, 309, 311, 312, 314, 315, 317, 325, 332, 334, 360, 376, 380, 382, 384, 385, 386, 387, 389, 424, 428, 433, 434, or 436 (EU numbering) relative to a native human Fc constant region. In some embodiments, the substitutions are: methionine for glycine at position 237; alanine for proline at position 238; lysine for serine at position 239; isoleucine for lysine at position 248; alanine, phenylalanine, isoleucine, methionine, glutamine, serine, valine, tryptophan, or tyrosine for threonine at position 250; phenylalanine, tryptophan, or tyrosine for methionine at position 252; threonine for serine at position 254; glutamic acid for arginine at position 255; aspartic acid, glutamic acid for threonine at position 256. or glutamine; alanine, glycine, isoleucine, leucine, methionine, asparagine, serine, threonine, or valine for proline at position 257; histidine for glutamic acid at position 258; alanine for aspartic acid at position 265; phenylalanine for aspartic acid at position 270; alanine or glutamic acid for asparagine at position 286; histidine for threonine at position 289; alanine for asparagine at position 297; glycine for serine at position 298; alanine for valine at position 303; alanine for valine at position 305;at position 307, alanine, aspartic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, valine, tryptophan, or tyrosine for threonine; at position 308, alanine, phenylalanine, isoleucine, leucine, methionine, proline, glutamine, or threonine for valine; at position 309, alanine, aspartic acid, glutamic acid, proline, or arginine for leucine or valine; arginine; alanine, histidine, or isoleucine for glutamine at position 311; alanine or histidine for aspartic acid at position 312; lysine or arginine for leucine at position 314; alanine or histidine for asparagine at position 315; alanine for lysine at position 317; glycine for asparagine at position 325; valine for isoleucine at position 332; leucine for lysine at position 334; histidine for lysine at position 360 alanine for aspartic acid at position 376; alanine for glutamic acid at position 380; alanine for glutamic acid at position 382; alanine for asparagine or serine at position 384; aspartic acid or histidine for glycine at position 385; proline for glutamine at position 386; glutamic acid for proline at position 387; alanine or serine for asparagine at position 389; alanine for serine at position 424; methionine at position 428 at position 435; alanine, aspartic acid, phenylalanine, glycine, histidine, isoleucine, lysine, asparagine, proline, glutamine, serine, threonine, valine, tryptophan, or tyrosine at position 436; lysine at position 433; alanine, phenylalanine, histidine, serine, tryptophan, or tyrosine at position 434; and histidine at position 436, all according to EU numbering.
[0060] In some embodiments, an anti-C5 antibody suitable for use in the methods described herein comprises a heavy chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 14, and / or a light chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 11. Alternatively, in some embodiments, an anti-C5 antibody for use in the methods described herein comprises a heavy chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 20, and / or a light chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 11.
[0061] In one embodiment, the antibody has an affinity dissociation constant (K) of at least 0.1 (e.g., at least 0.15, 0.175, 0.2, 0.25, 0.275, 0.3, 0.325, 0.35, 0.375, 0.4, 0.425, 0.45, 0.475, 0.5, 0.525, 0.55, 0.575, 0.6, 0.625, 0.65, 0.675, 0.7, 0.725, 0.75, 0.775, 0.8, 0.825, 0.85, 0.875, 0.9, 0.925, 0.95 or 0.975) nM. D ) at pH 7.4 and 25C (or alternatively under physiological conditions). In some embodiments, the K D is 1 nM or less (e.g., 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, or 0.2 nM or less).
[0062] In another embodiment, the K of an antibody against C5 at pH 6.0 and 25° C. D ) / (K of antibody against C5 at pH 7.4, 25C D)] is greater than 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 700, 750, 800, 850, 900, 950, 1000, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, (greater than 0, 250, 260, 270, 280, 290, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500 or 8000).
[0063] Methods for determining whether an antibody binds to a protein antigen and / or the affinity of an antibody for a protein antigen are known in the art. Binding of an antibody to a protein antigen can be detected by, for example, but not limited to, Western blots, dot blots, surface plasmon resonance (SPR) detection (e.g., the BIAcore system; Pharmacia Biosensor AB, Uppsala, Sweden, and Piscataway, NJ), or enzyme-linked immunosorbent assays (ELISA; Benny KC Lo (2004) "Antibody Engineering: Methods and Protocols," Humana Press (ISBN: 1588290921); Johne, B. et al., J. Immunol. Meth., 160:191-8, 1993; Jonsson, U. et al., Ann. Biol. Clin., 51:19-26 ... The affinity of the target molecule can be detected and / or quantified using a variety of techniques, such as those described in the Examples, for example, US Pat. No. 6,313,141 (Eds. et al., Biotechniques, 11:620-7, 1991). Methods for measuring affinity (e.g., dissociation and association constants) are further described in the Examples.
[0064] As used herein, "K a The term "k" refers to the rate constant for association of an antibody to an antigen. d" refers to the rate constant for dissociation of an antibody from the antibody / antigen complex. And "K D " refers to the equilibrium dissociation constant of an antibody-antigen interaction. The equilibrium dissociation constant is determined by the kinetic rate constant, K D =k a / k d Such determinations can be measured, for example, at 25C or 37C (see Examples). The kinetics of antibody binding to human C5 can be determined, for example, at pH 8.0, 7.4, 7.0, 6.5 and 6.0 via SPR on a BIAcore 3000 instrument using an anti-Fc antibody capture method to immobilize the antibody.
[0065] In one embodiment, the anti-C5 antibody or antigen-binding fragment thereof blocks the cleavage of C5 into C5a and C5b, thereby inhibiting, for example, the pro-inflammatory effects of C5a and the formation of the C5b-9 membrane attack complex (MAC) on the cell surface.
[0066] Methods for determining whether a particular antibody described herein inhibits C5 cleavage are known in the art. Inhibition of human complement component C5 can reduce the cytolytic ability of complement in a subject's body fluid. Such a reduction in the cytolytic ability of complement present in a body fluid can be measured, for example, by a conventional hemolytic assay, such as a hemolytic assay (Kabat and Mayer (eds.), "Experimental Immunochemistry, 2001, 14:131-135). ndEdition," 135-240, Springfield, IL, CC Thomas (1961), pages 135-139) or conventional variations of that assay, such as the chicken erythrocyte hemolysis method (Hillmen, P. et al., N. Engl. J. Med., 350:552-9, 2004)., 350:552-9, 2004). Methods for determining whether a candidate compound inhibits the cleavage of human C5 into its forms C5a and C5b are known in the art (Evans, M. et al., J. Engl. J. Med., 350:552-9, 2004). al., Mol. Immunol., 32:1183-95, 1995). The concentration and / or physiological activity of C5a and C5b in body fluids can be measured, for example, by methods known in the art. For C5b, a hemolytic assay or an assay for soluble C5b-9 as described herein can be used. Other assays known in the art can also be used. These assays, or other suitable assay types, can be used to screen candidate agents capable of inhibiting human complement component C5.
[0067] Immunologic techniques, such as, for example and without limitation, ELISA, can be used to measure protein concentrations of C5 and / or its cleavage products to determine the ability of an anti-C5 antibody or antigen-binding fragment thereof to inhibit conversion of C5 to biologically active products. In some embodiments, the generation of C5a is measured. In some embodiments, a C5b-9 neoepitope-specific antibody is used to detect MAC formation.
[0068] The hemolysis assay can be used to determine the inhibitory activity of anti-C5 antibody or its antigen-binding fragment against complement activation. To determine the effect of anti-C5 antibody or its antigen-binding fragment against classical complement pathway-mediated hemolysis in an in vitro serum test solution, for example, sheep red blood cells coated with hemolysin or chicken red blood cells sensitized with anti-chicken red blood cell antibody are used as target cells. The hemolysis percentage is normalized by taking the lysis occurring in the absence of inhibitor as 100% lysis. In some embodiments, the classical complement pathway is activated by human IgM antibody, for example, when utilized in the Wieslab® Classical Pathway Complement Kit (Wieslab® COMPL CP310, Euro-Diagnostica, Sweden). Briefly, the test serum is incubated with anti-C5 antibody or its antigen-binding fragment in the presence of human IgM antibody. The amount of C5b-9 produced is measured by contacting the mixture with an enzyme conjugated with an anti-C5b-9 antibody and a fluorogenic substrate and measuring the absorbance at an appropriate wavelength. As a control, the test serum is incubated in the absence of an anti-C5 antibody or an antigen-binding fragment thereof. In some embodiments, the test serum is a C5-deficient serum reconstituted with a C5 polypeptide.
[0069] To determine the effect of anti-C5 antibodies or antigen-binding fragments thereof on alternative pathway-mediated hemolysis, non-susceptible rabbit or guinea pig red blood cells can be used as target cells. In some embodiments, the serum test solution is C5-deficient serum reconstituted with C5 polypeptide. The hemolysis percentage is normalized by taking the lysis occurring in the absence of inhibitors as 100% lysis. In some embodiments, the alternative complement pathway is activated by lipopolysaccharide molecules, for example when utilized in the Wieslab® Alternative Pathway Complement Kit (Wieslab® COMPL AP330, Euro-Diagnostica, Sweden). Briefly, the test serum is incubated with anti-C5 antibodies or antigen-binding fragments thereof in the presence of lipopolysaccharide. The amount of C5b-9 produced is measured by contacting the mixture with an enzyme conjugated to anti-C5b-9 antibodies and a fluorogenic substrate and measuring the fluorescence at the appropriate wavelength. As a control, test sera are incubated in the absence of anti-C5 antibody or antigen-binding fragment thereof.
[0070] In some embodiments, C5 activity or its inhibition is quantified using a CH50eq assay. The CH50eq assay is a method for measuring total classical complement activity in serum. This test is a lytic assay that uses antibody-sensitized red blood cells as an activator of the classical complement pathway and various dilutions of test serum to determine the amount required to obtain 50% lysis (CH50). The percentage of hemolysis can be determined, for example, using a spectrophotometer. The CH50eq assay provides an indirect measure of terminal complement complex (TCC) formation, and TCC itself is the direct cause of the hemolysis measured. This assay is known and commonly performed by those skilled in the art. Briefly, undiluted serum samples (e.g., reconstituted human serum samples) are added to microassay wells containing antibody-sensitized red blood cells to activate the classical complement pathway, and TCC is generated. The activated serum is then diluted in microassay wells coated with a capture reagent (e.g., an antibody that binds to one or more components of TCC). TCC present in the activated sample binds to the monoclonal antibody that coats the surface of the microassay wells. The wells are washed and a detection reagent that is detectably labeled and recognizes the bound TCC is added to each well. The detectable label may be, for example, a fluorescent label or an enzyme label. The results of the assay are expressed in CH50 unit equivalents per milliliter (CH50 U Eq / mL).
[0071] For example, inhibition when associated with terminal complement activity includes a decrease in terminal complement activity, e.g., in a hemolytic or CH50eq assay, of at least 5% (e.g., at least 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60%) as compared to the effect of a control antibody (or antigen-binding fragment thereof) under similar conditions and at equimolar concentrations. As used herein, substantial inhibition refers to an inhibition of a given activity (e.g., terminal complement activity) of at least 40% (e.g., at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% or more). In some embodiments, the anti-C5 antibodies described herein contain one or more amino acid substitutions compared to the CDRs of eculizumab (i.e., SEQ ID NOs:1-6), but retain at least 30% (e.g., at least 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90 or 95%) of the complement inhibitory activity of eculizumab in a hemolytic assay or a CH50eq assay.
[0072] The anti-C5 antibodies described herein have a serum half-life in humans of at least 20 days (e.g., at least 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 or 55 days). In another embodiment, the anti-C5 antibodies described herein have a serum half-life in humans of at least 40 days. In another embodiment, the anti-C5 antibodies described herein have a serum half-life in humans of approximately 43 days. In another embodiment, the anti-C5 antibodies described herein have a serum half-life in humans of 39-48 days. Methods for measuring the serum half-life of an antibody are known in the art. In some embodiments, the anti-C5 antibodies or antigen-binding fragments thereof described herein have a serum half-life that is at least 20% (e.g., at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 400, or 500%) greater than the serum half-life of eculizumab, e.g., as measured in one of the mouse model systems described in the Examples (e.g., a C5-deficient / NOD / scid mouse model system or an hFcRn transgenic mouse model system).
[0073] In one embodiment, the antibody competes for binding to the same epitope on C5 as the antibodies described herein and / or binds to the same epitope on C5 as the antibodies described herein. The term "binds to the same epitope" in reference to two or more antibodies means that the antibodies bind to the same segment of amino acid residues as determined by a given method. Techniques for determining whether an antibody binds to the same epitope on C5 as the antibodies described herein include epitope mapping methods, such as, for example, X-ray analysis of crystals of antigen-antibody complexes, and hydrogen / deuterium exchange mass spectrometry (HDX-MS). Other methods monitor the binding of antibodies to peptide antigen fragments or mutant variations of antigens, where loss of binding due to modification of amino acid residues in the antigen sequence is often considered to be an indication of epitope components. Additionally, computational combinatorial methods for epitope mapping can also be used. These methods rely on the ability of the antibody of interest to affinity isolate specific short peptides from combinatorial phage display peptide libraries. Antibodies with the same VH and VL or the same CDR1, CDR2 and CDR3 sequences are expected to bind to the same epitope.
[0074] An antibody that "competes with another antibody for binding to a target" refers to an antibody that inhibits (partially or completely) the binding of the other antibody to the target. Whether two antibodies compete with each other for binding to a target, i.e., whether and to what extent one antibody inhibits the binding of the other antibody to the target, can be determined using known competition experiments. In certain embodiments, an antibody competes with another antibody to inhibit the binding of the other antibody to the target by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. The level of inhibition or competition can be different depending on which antibody is the "blocking antibody" (i.e., the antibody that is first incubated with the target). Competing antibodies can, for example, bind to the same epitope, overlapping epitopes, or adjacent epitopes (e.g., as evidenced by steric hindrance).
[0075] The anti-C5 antibodies, or antigen-binding fragments thereof, described herein and used in the methods described herein can be generated using a variety of techniques recognized in the art. Monoclonal antibodies can be obtained by a variety of techniques well known to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, usually by fusion with a myeloma cell (Kohler, G. & Milstein, C., Eur. J. Immunol., 6:511-9, 1976)). Immortalization methods include transformation with Epstein-Barr virus, oncogenes, or retroviruses, or other methods known in the art. Colonies arising from a single immortalized cell are screened for production of antibodies with the desired specificity and affinity for the antigen, and the yield of monoclonal antibodies produced by such cells may be enhanced by a variety of techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, DNA sequences encoding monoclonal antibodies or binding fragments thereof may be isolated by screening a DNA library from human B cells (Huse, W. et al., Science, 246:1275-81, 1989).
[0076] III. Composition Also provided herein is a composition comprising an anti-C5 antibody or an antigen-binding fragment thereof. In one embodiment, the composition comprises an anti-C5 antibody comprising a CDR1, CDR2, and CDR3 domain in a heavy chain variable region having a sequence set forth in SEQ ID NO: 12, and a CDR1, CDR2, and CDR3 domain in a light chain variable region having a sequence set forth in SEQ ID NO: 8. In another embodiment, the anti-C5 antibody comprises a heavy chain and a light chain having the sequences set forth in SEQ ID NO: 14 and 11, respectively. In another embodiment, the anti-C5 antibody comprises a heavy chain and a light chain having the sequences set forth in SEQ ID NO: 20 and 11, respectively.
[0077] The composition may be formulated as a pharmaceutical solution, for example, for administration to a subject for the treatment or prevention of a complement-associated disorder. A pharmaceutical composition generally comprises a pharma-ceutically acceptable carrier. As used herein, "pharma-ceutically acceptable carrier" refers to and includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are physiologically compatible. The composition may comprise a pharma-ceutically acceptable salt, for example, an acid or base addition salt, a sugar, a carbohydrate, a polyol, and / or a tonicity adjusting agent.
[0078] The compositions can be formulated according to standard methods. Pharmaceutical formulation is a well-established technique (see, e.g., Gennaro (2000) "Remington: The Science and Practice of Pharmacy," 2006). th Edition, Lippincott, Williams & Wilkins (ISBN: 0683306472); Ansel et al. (1999) “Pharmaceutical Dosage Forms and Drug Delivery Systems,” 7 th Edition, Lippincott Williams & Wilkins Publishers (ISBN:0683305727); and Kibbe (2000) “Handbook of Pharmaceutical Excipients American Pharmaceutical Association,”3 rdEdition (ISBN:091733096X). In some embodiments, the compositions may be formulated, for example, at an appropriate concentration and as a buffer solution suitable for storage at 2-8C (e.g., 4C). In some embodiments, the compositions may be formulated for storage at temperatures below 0C (e.g., -20C or -80C). In some embodiments, the compositions may be formulated for storage at 2-8C (e.g., 4C) for up to 2 years (e.g., 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 1.5 years, or 2 years). Thus, in some embodiments, the compositions described herein are stable in storage at 2-8C (e.g., 4C) for at least 1 year.
[0079] Pharmaceutical compositions can be in various forms. These forms include liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injections and infusions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form depends in part on the intended mode of administration and therapeutic application. Compositions containing compositions intended for systemic or local delivery can be in the form of, for example, injectable or infusible solutions. Thus, compositions can be formulated for parenteral administration (e.g., intravenous, subcutaneous, intraperitoneal or intramuscular injection). As used herein, "parenteral administration," "administered parenterally," and other grammatically equivalent terms refer to modes of administration other than enteral and topical administration, which are usually performed by injection, including, but not limited to, intravenous, intranasal, intraocular, pulmonary, intramuscular, intra-arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intrapulmonary, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intrathecal, epidural, intracerebral, intracranial, intracarotid, and substernal injection and infusion.
[0080] IV. Outcome aHUS is an extremely rare disease caused by chronically uncontrolled complement activation. Persistent complement dysregulation leads to systemic enhanced C5 activation and subsequent terminal complement activation, which contributes to the devastating clinical manifestations of this disorder. Patients with aHUS are at risk for significant morbidity and mortality.
[0081] aHUS may be hereditary, acquired, or idiopathic. Hereditary aHUS may be associated with mutations in many human complement components, including, for example, complement factor H (CFH), membrane cofactor protein (MCP), complement factor I (CFI), C4b-binding protein (C4BP), complement factor B (CFB), and complement factor 3 (C3) (Caprioli, J. et al., Blood, 108:1267-79, 2006). Specific mutations in the gene encoding CD55 have not yet been implicated in aHUS, but are associated with the severity of aHUS (Esparza-Gordillo, J. et al., Hum. Mol. Genet., 14:703-12, 2005). aHUS may be considered hereditary when two or more members of the same family (e.g., three, four, five, six or more) suffer from the disease at least six months apart and exposure to a common precipitating agent has been ruled out, or when one or more aHUS-associated genetic mutations (e.g., one or more mutations in CFH, MCP / CD46, CFB, or CFI) have been identified in the subject. For example, a subject may have CFH-associated aHUS, CFB-associated aHUS, CFI-associated aHUS, or MCP-associated aHUS. Up to 30% of hereditary aHUS cases are associated with mutations in CFH, 12% with mutations in MCP, 5-10% with mutations in CFI, and less than 2% with mutations in CFB. Hereditary aHUS may be multiplex (i.e., familial; there are two or more affected family members) or simplex (i.e., only one member of a family occurs). aHUS may be considered acquired if a causative environmental factor (e.g., a drug, systemic disease, or a virus or bacterial agent that does not produce Shiga-like exotoxins) or precipitant can be identified. aHUS may be considered idiopathic when no precipitant (genetic or environmental) is evident.
[0082] aHUS is rare, with a mortality rate of up to 25%. Many patients with the disease suffer from permanent neurological or renal damage, for example at least 50% of aHUS patients progress to end-stage renal failure (ESRF) (Kavanagh, D. et al., Br. Med. Bull., 77-78:5-22, 2006). Until recently, treatment options for aHUS patients were limited, often involving plasma infusion or plasma exchange. In some cases, aHUS patients have undergone unilateral or bilateral nephrectomy or kidney transplantation (Artz, M. et al., Transplantation, 76:821-6, 2003). However, disease recurrence is common in treated patients.
[0083] A laboratory test may be performed to determine whether a human subject has thrombocytopenia, microangiopathic hemolytic anemia, or acute renal insufficiency. Thrombocytopenia is defined by a medical professional as: (i) 150,000 / mm 3 Platelet count less than 60,000 / mm 3(ii) decreased platelet survival time, reflecting increased destruction of platelets in the circulation; and (iii) large platelets seen on peripheral smears, consistent with secondary activation of thrombopoiesis. Microangiopathic hemolytic anemia is defined by health professionals as having (i) a hemoglobin concentration less than 10 mg / dL (e.g., less than 6.5 mg / dL), (ii) an elevated serum lactate dehydrogenase (LDH) concentration (>460 U / L), (iii) hyperbilirubinemia, reticulocytosis, low or undetectable circulating free hemoglobin, and haptoglobin concentrations, and (iv) detection of fragmented red blood cells (schistocytes) in peripheral smears, typically with a negative Coombs test for either acanthocytes or helmet cells (Kaplan et al. (1992) “Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura,” Informa Health Care (ISBN 0824786637) and Zipfel (2005) “Complement and Kidney Disease,” Springer (ISBN 3764371668)). Blood levels of C3 and C4 can also be used as a measure of complement activation or complement dysregulation. In addition, the subject's condition can be further characterized by identifying the subject as carrying one or more mutations in genes associated with aHUS, such as, for example, CFI, CFB, CFH, or MCP (above). Suitable methods for detecting mutations in genes include, for example, DNA sequence analysis and nucleic acid array technology (Breslin, E. et al., Clin. Am. Soc. Nephrol., 1:88-99, 2006; Goicoechea de Jorge, E. et al., Proc. Natl. Acad. Sci. USA, 104:240-5, 2007).
[0084] Provided herein is a method for treating aHUS in a pediatric patient, comprising administering an anti-C5 antibody to the patient. Symptoms of aHUS include, but are not limited to, severe hypertension, urinary protein, uremia, fatigue / fatigue, irritability, thrombocytopenia, microangiopathic hemolytic anemia, and renal dysfunction (e.g., acute renal failure). Patients treated according to the methods disclosed herein preferably experience an improvement in at least one symptom of aHUS. Treatment may, for example, produce at least one therapeutic effect selected from the group consisting of a reduction or cessation in severe hypertension, urinary protein, uremia, fatigue / fatigue, irritability, thrombocytopenia, microangiopathic hemolytic anemia, and renal dysfunction (e.g., acute renal failure) compared to baseline.
[0085] In another embodiment, the treatment results in substantial or complete inhibition of thrombotic microangiopathy (TMA). In another embodiment, the treatment results in substantial or complete inhibition of thrombotic microangiopathy, which inhibition is maintained for, e.g., more than 170 days (e.g., more than 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 205, 210, 215, 220, or 225 days) after initiation of treatment.
[0086] In another embodiment, the treatment results in an increase in platelet count compared to baseline. In another embodiment, the treatment results in a decrease in serum creatinine levels compared to baseline. In a particular embodiment, the treatment results in a 25% or greater decrease in serum creatinine levels compared to baseline.
[0087] In another embodiment, the treatment results in a shift in factor Ba, soluble tumor necrosis factor receptor 1 (sTNFR1), soluble vascular adhesion molecule 1 (sVCAM1), thrombomodulin, D-dimer, and cystatin C towards normal levels.
[0088] In another embodiment, treatment results in a decrease in the need for blood transfusions compared to baseline.
[0089] In another embodiment, the treatment eliminates the need for the patient to undergo dialysis, hi another embodiment, the patient stops dialysis within 35 days (e.g., 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, or 10 days) of starting treatment.
[0090] In another embodiment, treatment results in a reduction in major adverse vascular events (MAVE, e.g., venous / deep vein thrombosis, pulmonary artery embolism, myocardial infarction, transient ischemic attack, unstable angina, renal vein / renal artery thrombosis / glomerular thrombosis, renal infarction, acute peripheral vascular occlusion, mesenteric / splanchnic venous / arterial thrombosis or infarction, hepatic / portal vein thrombosis, cerebral artery occlusion / cerebrovascular disease, cerebral venous occlusion, renal artery thrombosis, or multi-infarct dementia).
[0091] In certain embodiments, the treatment produces a change from baseline in quality of life as assessed via the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale, 4th edition, and the European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30 Scale. In one embodiment, the treatment produces a change from baseline in quality of life of 1 or more points (e.g., 1, 2, or 3) as assessed via the FACIT-Fatigue scale. In another embodiment, treatment is associated with a 3 point change from baseline in quality of life as assessed via the FACIT-Fatigue scale for 150 days or more (e.g., 150 days, 151 days, 152 days, 153 days, 154 days, 155 days, 156 days, 157 days, 158 days, 159 days, 160 days, 161 days, 162 days, 163 days, 164 days, 165 days, 166 days, 167 days, 168 days, 169 days, 170 days, or more) after initiation of treatment. , 171 days, 172 days, 173 days, 174 days, 175 days, 176 days, 177 days, 178 days, 179 days, 180 days, 181 days, 182 days, 183 days, 184 days, 185 days, 186 days, 187 days, 188 days, 189 days, 190 days, 191 days, 192 days, 193 days, 194 days, 195 days, 196 days, 197 days, 198 days, 199 days, 200 days, 205 days, 210 days, 215 days, 220 days or 225 days).
[0092] In another embodiment, the patient's chronic kidney disease (CKD) improves by one or more stages after initiation of treatment. For example, the patient's CKD improves by 1, 2, 3, 4, or 5 stages. In another embodiment, the patient's CKD improves by 150 days or more (e.g., 150 days, 151 days, 152 days, 153 days, 154 days, 155 days, 156 days, 157 days, 158 days, 159 days, 160 days, 161 days, 162 days, 163 days, 164 days, 165 days, 166 days, 167 days, 168 days, 169 days, 170 days, 171 days, 172 days, 173 days, 174 days, 175 days, 176 days, 177 days, 178 days, 179 days, 180 days, 181 days, 182 days, 183 days, 184 days, 185 days, 186 days, 187 days, 188 days, 189 days, 190 days, 191 days, 192 days, 193 days, 194 days, 195 days, 196 days, 197 days, 198 days, 199 days, 200 days, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2030 days, 177 days, 178 days, 179 days, 180 days, 181 days, 182 days, 183 days, 184 days, 185 days, 186 days, 187 days, 188 days, 189 days, 190 days, 191 days, 192 days, 193 days, 194 days, 195 days, 196 days, 197 days, 198 days, 199 days, 200 days, 205 days, 210 days, 215 days, 220 days or 225 days), improving by one or more stages.
[0093] In another embodiment, lactate dehydrogenase (LDH) levels can be used to assess responsiveness to treatment (e.g., a decrease in hemolysis as assessed by lactate dehydrogenase (LDH) levels indicates an improvement in at least one symptom of aHUS). LDH is a marker of intravascular hemolysis (Hill, A. et al., Br. J. Haematol., 149: 414-25, 2010; Hillmen, P. et al., N. Engl. J. Med., 350: 552-9, 2004; Parker, C. et al., Blood, 106: 3699-709, 2005). Red blood cells contain large amounts of LDH, and correlations between cell-free hemoglobin and LDH concentrations have been reported in vitro (Van Lente, F. et al., Clin. Chem., 27: 1453-5, 1981) and in vivo (Kato, G. et al., Blood, 107: 2279-85, 2006). The outcome of hemolysis is independent of anemia (Hill, A. et al., Haematologica, 93(s1):359 Abs.0903, 2008; Kanakura, Y. et al., Int. J. Hematol., 93:36-46, 2011). LDH concentrations obtained at baseline and then serially throughout the treatment period are important measures of hemolysis. Reference values of cell-free plasma hemoglobin are highly elevated in aHUS patients with LDH ≥ 1.5 times the upper limit of normal (LDH ≥ 1.5xULN), and there is a significant correlation between LDH and cell-free plasma hemoglobin (Hillmen, P. et al., N. Engl. J. Med., 355:1233-43, 2006). Normal LDH values range from 105 to 333 IU / L (international units per liter).
[0094] LDH levels can be measured using any suitable test or assay, such as those described by Ferri FF, ed. Ferri's Clinical Advisor 2014. Philadelphia PA: Elsevier Mosby; 2014: Section IV-Laboratory tests and interpretation of results. LDH concentrations can be measured in a variety of samples obtained from patients, particularly serum samples. As used herein, the term "sample" refers to biological material from a subject. Although serum LDH concentrations are of interest, samples can be derived from other sources, including, for example, single cells, multiple cells, tissues, tumors, biofluids, biomolecules, or supernatants or extracts of any of the foregoing. Examples include tissues removed for biopsy, tissues removed during resection, blood, urine, lymphatic tissue, lymphatic fluid, cerebrospinal fluid, mucus, and stool samples. The samples used can vary based on the assay format, detection method, and the nature of the tumor, tissue, cell, or extract being assayed. Methods for preparing samples are known in the art and can be readily adapted to obtain a sample that is compatible with the method utilized.
[0095] In one embodiment, a patient treated according to the disclosed methods experiences a decrease in LDH levels to normal or within 10% or 20% above what is considered normal (e.g., within 105-333 IU / L). In one embodiment, the patient's LDH levels are 1.5 times or greater above the upper limit of normal (LDH≧1.5×ULN) prior to the start of treatment.
[0096] V. Kits and Unit Dosage Forms Further provided herein is a kit comprising a pharmaceutical composition comprising an anti-C5 antibody or an antigen-binding fragment thereof (e.g., ravulizumab, or BNJ421) in a therapeutically effective amount adapted for use in the preceding method, and a pharma- ceutically acceptable carrier. The kit can also optionally comprise instructions, including, for example, an administration schedule, to allow a practitioner (e.g., a doctor, a nurse, or a patient) to administer the composition contained therein, and administer the composition to a patient with aHUS. The kit also comprises a syringe.
[0097] Optionally, the kit includes multiple packages of single-dose pharmaceutical compositions, each containing an effective amount of anti-C5 antibody or antigen-binding fragment thereof, for single administration according to the above-mentioned method.The apparatus or device required for administration of the pharmaceutical composition may also be included in the kit.For example, the kit may provide one or more pre-filled syringes containing a certain amount of anti-C5 antibody or antigen-binding fragment thereof.
[0098] In one embodiment, a kit for treating aHUS in a human pediatric patient includes (a) a dose of an anti-C5 antibody or antigen-binding fragment thereof comprising CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO: 12 and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO: 8, and (b) instructions for using the anti-C5 antibody or antigen-binding fragment thereof according to any of the methods described herein.
[0099] In one embodiment, the kit comprises a dose of an anti-C5 antibody or antigen-binding fragment thereof, which is administered to a pediatric patient weighing 5 kg or more and less than 10 kg in the following doses: (a) a 300 mg dose once on day 1, and (b) a 300 mg dose once on day 15 and every 4 weeks thereafter.
[0100] In one embodiment, the kit comprises a dose of an anti-C5 antibody or antigen-binding fragment thereof, which is administered to a patient weighing 5 kg or more and less than 10 kg at (a) a dose of 600 mg once on day 1, and (b) a dose of 300 mg on day 15 and every 4 weeks thereafter.
[0101] In another embodiment, the kit comprises a dose of an anti-C5 antibody or antigen-binding fragment thereof, which is administered to a patient weighing 10 kg or more and less than 20 kg at (a) a dose of 600 mg once on day 1, and (b) a dose of 600 mg on day 15 and every 4 weeks thereafter.
[0102] In another embodiment, the kit comprises a dose of an anti-C5 antibody or antigen-binding fragment thereof, which is administered to a patient weighing 20 kg or greater and less than 30 kg at (a) a dose of 900 mg once on day 1, and (b) a dose of 2100 mg on day 15 and every 8 weeks thereafter.
[0103] In another embodiment, the kit comprises a dose of an anti-C5 antibody or antigen-binding fragment thereof, which is administered to a patient weighing 30 kg or greater and less than 40 kg at (a) a dose of 1200 mg once on day 1, and (b) a dose of 2700 mg on day 15 and every 8 weeks thereafter.
[0104] In another embodiment, the kit comprises a dose of an anti-C5 antibody or antigen-binding fragment thereof, which is administered to a patient weighing 40 kg or greater and less than 60 kg at (a) a dose of 2400 mg once on day 1, and (b) a dose of 3000 mg on day 15 and every 8 weeks thereafter.
[0105] In another embodiment, the kit comprises a dose of an anti-C5 antibody or antigen-binding fragment thereof, which is administered to a patient weighing 60 kg or greater and less than 100 kg at (a) a dose of 2700 mg once on day 1, and (b) a dose of 3300 mg on day 15 and every 8 weeks thereafter.
[0106] In another embodiment, the kit comprises a dose of an anti-C5 antibody or antigen-binding fragment thereof, which is administered to a patient weighing 100 kg or more at (a) a dose of 3000 mg once on day 1, and (b) a dose of 3600 mg on day 15 and every 8 weeks thereafter.
[0107] The following examples are merely illustrative and should not be construed as limiting the scope of the disclosure in any way, although numerous variations and equivalents will become apparent to those of ordinary skill in the art upon reading the present disclosure. The contents of all references, Genbank entries, patents and published patent applications cited throughout this specification are expressly incorporated herein by reference. EXAMPLES
[0108] Example 1: A Phase III, Open-Label, Multicenter Study of ravulizumab in Children and Adolescents with aHUS A phase III, single-arm, multicenter study will be conducted to evaluate the safety, efficacy, pharmacokinetics, and pharmacology of ravulizumab administered by intravenous (IV) infusion in approximately 23-28 pediatric patients ages birth-18 years with a confirmed diagnosis of aHUS. The study has two cohorts. Cohort 1 includes complement inhibitor-naïve patients. Cohort 2 includes adolescent patients (ages 12-18 years) previously treated with eculizumab. The study will consist of a screening period (up to 7 days for cohort 1 or up to 28 days for cohort 2), a 26-week initial evaluation period, and a 2-year extension period. The study design is shown in Figure 1.
[0109] Approximately 23 to 28 pediatric patients with documented aHUS are expected. The minimum number of patients in each age category is as follows: (1) birth to <2 years of age: 4 patients, (2) 2 to <6 years of age: 4 patients, (3) 6 to <12 years of age: 4 patients, and (4) 12 to <18 years of age: 8 patients. Patients in Cohort 2 must be between 12 and <18 years of age.
[0110] Consented patients in Cohort 1 will be screened for study eligibility up to 7 days prior to Day 1. Consented patients in Cohort 2 will be screened for study eligibility up to 28 days prior to Day 1. The first dose of study drug will be administered 14 days after the eligible patient's last eculizumab dose. Patients who are eligible based on the inclusion and exclusion criteria will be enrolled in the initial evaluation period and will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment of ravulizumab on Day 15 and once every 8 weeks (q8w) for patients weighing 20 kg or more and once every 4 weeks (q4w) for patients weighing less than 20 kg, for a total of 26 weeks of treatment. As shown in Table 1 below, weight-based dosing is based on the patient's weight recorded on the dosing regimen determination date (if the dosing regimen date is the dosing date, weight is recorded prior to dosing). [Table 1-1]
[0111] An initial analysis, including review of ULTOMIRIS PK and serum free C5 levels, will be conducted after four complement inhibitor-naïve patients weighing ≥5 kg and <40 kg (i.e., Cohort 1) have completed dosing through Day 71. Additionally, safety data will be reviewed. Patient enrollment will proceed without interruption while the analysis is ongoing. The primary objective of this review is to ensure that patients are adequately complement-inhibited during the study, with the goal of achieving complete terminal complement blockade being met. Based on this review, if dose adjustments are necessary and deemed tolerable, subsequent treatment for all patients will continue with the adjusted dosing regimen. After the initial evaluation period, patients will enter an extension period during which all patients will continue to receive a weight-based maintenance dose of ULTOMIRIS PK and serum free C5 levels until the product is registered or approved (subject to country-specific regulations) or for up to two years, whichever occurs first. Note that q4w visits during the extension period do not apply to patients weighing ≥20 kg and receiving ULTOMIRIS q8w. End of study will be defined as the patient's last visit or follow-up (at site or by phone), whichever occurs later, at the end of the 2-year extension period.
[0112] 1. Purpose The primary objective of this study was to evaluate the efficacy of ravulizumab in inhibiting complement-mediated thrombotic microangiopathy (TMA), characterized by thrombocytopenia, hemolysis, and renal dysfunction, in complement inhibitor-naïve pediatric patients with aHUS (i.e., cohort 1).
[0113] Secondary objectives for complement inhibitor-naïve patients (i.e., Cohort 1) were: (1) characterization of the safety and tolerability of ULTOMIRIS; (2) evaluation of the need for dialysis, time to complete TMA remission, complete TMA remission status over time, observed and change from baseline in estimated glomerular filtration rate (eGFR), stage of chronic kidney disease (CKD) as assessed by eGFR at the selected target date and classified as improved, stable (no change), or worsening compared to baseline, observed and change from baseline in hematological parameters (platelets, lactate dehydrogenase [LDH], hemoglobin), and at least (3) characterization of the pharmacokinetic (PK) / pharmacodynamic (PD) properties of ULTOMIRIS, including serum ULTOMIRIS concentrations over time and serum free complement component 5 (C5) concentrations over time; and (4) evaluation of the long-term safety and efficacy of ULTOMIRIS.
[0114] Secondary objectives for patients previously treated with eculizumab (i.e., Cohort 2) were: (1) characterization of the safety and tolerability of ULTOMIRIS; (2) evaluation of the efficacy of ULTOMIRIS in terms of the need for dialysis, observed and change from baseline in eGFR, CKD stage as assessed by eGFR at the selected target date and classified as improved, stable (no change), or worsening compared to baseline, observed and change from baseline in hematological parameters (platelets, LDH, hemoglobin), and change from baseline in QoL as measured by the Pediatric FACIT-Fatigue questionnaire; (3) characterization of the PK / PD of ULTOMIRIS, including the change over time in serum ULTOMIRIS concentrations and the change over time in serum free C5 concentrations; and (4) evaluation of the long-term safety and efficacy of ULTOMIRIS.
[0115] 2. Diagnosis and main inclusion and exclusion criteria Patients must meet all inclusion and exclusion criteria to receive a confirmed diagnosis of aHUS and be eligible for the study. Patients who fail any of the eligibility criteria may be rescreened. Patients may be rescreened up to two times. For cohort 1, samples collected at screening may be tested at either the local or central clinical laboratory. If a local clinical laboratory is used to define eligibility, additional samples for LDH, platelet count, hemoglobin, and serum creatinine will be collected during the screening period and tested at the central clinical laboratory. All analyses of the study will be based on central clinical laboratory results (unless the result is missing). If a patient in cohort 1 is found to not meet the eligibility criterion for serum creatinine (inclusion criterion 2c) based on the central clinical laboratory results, the patient should not be enrolled in the study. If the subject has received the first dose of ravulizumab, the patient must be withdrawn from the study and may be replaced. For patients in cohort 1, laboratory test results for exclusion criterion 1 and / or exclusion criterion 2 may not be available prior to the first dose. Subsequent results regarding Exclusion Criterion 1 and / or Exclusion Criterion 2 may lead to discontinuation and replacement of patients.
[0116] For Cohort 2, samples collected at screening must be tested in a central clinical laboratory, except that medical history test results from chart review must be used for inclusion criterion 3 and exclusion criteria 1, 2, 3, and 24.
[0117] The following enrollment criteria apply to patients in both cohorts unless noted as specific to Cohort 1 or Cohort 2.
[0118] The inclusion criteria were as follows: 1. Patients aged between birth and 18 years old and weighing 5kg or more at the time of obtaining informed consent. Cohort 1 patients were not previously treated with complement inhibitors. b. Cohort 2 patients were 12 to <18 years of age and had been treated with eculizumab according to labeled dosing recommendations for aHUS for at least 90 days prior to screening. 2. For patients in Cohort 1, there must be evidence of TMA, including thrombocytopenia, evidence of hemolysis, and renal impairment, based on the following laboratory findings: a. A platelet count less than 150,000 per microliter (μL) during the screening period or within 28 days prior to the start of the screening period; and b. LDH ≥ 1.5 times the upper limit of normal (ULN) during the screening period or within 28 days prior to the start of the screening period, and hemoglobin ≤ the lower limit of normal (LLN) for age and sex during the screening period or within 28 days prior to the start of the screening period; and Serum creatinine level ≥ 97.5th percentile for age at screening (patients requiring dialysis for acute kidney injury regardless of serum creatinine level are also eligible). 3. For Cohort 2 patients, a documented diagnosis of aHUS including: At the time of the TMA event, an increase in LDH above the ULN, an increase in creatinine above the ULN, and a decrease in platelets below the LLN are recorded by the local clinical laboratory. 4. For patients in Cohort 2, clinical evidence of response to eculizumab as demonstrated by stable TMA parameters (per central clinical laboratory results) at screening, including: a. LDH < 1.5 × ULN, and b. Platelet count ≥ 150,000 / μL, and c. Using the Schwartz formula, eGFR > 30 mL / min / 1.73 m 2 5. Among kidney transplant recipients: A history of aHUS prior to the current kidney transplant, or b. No history of aHUS and evidence of persistent TMA at least 4 days after a change in calcineurin inhibitor (CNI; e.g., cyclosporine, tacrolimus) or mammalian target of rapamycin inhibitor (mTORi; e.g., sirolimus, everolimus) immunosuppressive regimen. 6. Among patients who developed postpartum TMA, evidence of persistent TMA for more than 3 days after delivery. 7. To reduce the risk of meningococcal disease (Neisseria meningitidis), all patients must be vaccinated against meningococcal disease within 3 years prior to or at the time of starting study drug. Patients who received meningococcal vaccination less than 2 weeks prior to starting ULTOMIRIS treatment must be treated with appropriate prophylactic antibiotics until 2 weeks after vaccination. Patients who have not been vaccinated prior to starting ULTOMIRIS treatment must receive prophylactic antibiotics prior to meningococcal vaccination and for at least 2 weeks after meningococcal vaccination. Patients who cannot be vaccinated must receive prophylactic antibiotics for the entire duration of treatment and for 8 months after the final dose. 8. Patients must be vaccinated against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae according to national and local vaccination schedule guidance. 9. Female patients of childbearing potential and male patients with female partners of childbearing potential must follow protocol-specified guidance regarding avoidance of pregnancy during treatment and for 8 months after the last dose of study drug. 10. The patient's legal guardian must be willing and able to provide written informed consent and the patient must be willing to provide written informed assent (as determined by the central or local Institutional Review Board [IRB] / Institutional (or Independent) Ethics Committee [IEC], if applicable) and to adhere to the schedule of study visits.
[0119] Exclusion criteria were as follows: 1. History of familial or acquired a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13' (ADAMTS13) deficiency (activity less than 5%). 2. History of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) as evidenced by a positive Shiga toxin test or culture of Shiga toxin-producing bacteria. 3. Direct Coombs test positive 4. History of human immunodeficiency virus (HIV) infection. 5. Non-resolved meningococcal disease. 6. Patients with confirmed active sepsis not treated with antibiotics as defined by a positive blood culture within 7 days prior to screening. 7. Presence or suspicion of an active, untreated systemic bacterial infection that, in the opinion of the investigator, would complicate the accurate diagnosis of aHUS or interfere with management of aHUS disease. 8.Women who are planning to become pregnant during the study period or who are currently pregnant or breastfeeding. 9. Heart, lung, small intestine, pancreas or liver transplantation. 10. Kidney transplant recipients with acute renal dysfunction within 4 weeks of transplantation consistent with a diagnosis of acute antibody-mediated rejection (AMR) according to the Banff 2013 criteria. 11. Non-kidney transplant recipients with a history of renal disease other than aHUS, such as known renal biopsy findings suggestive of an underlying condition other than aHUS, known renal ultrasound findings consistent with an alternative diagnosis of aHUS (e.g., small kidneys for age), or known family history and / or genetic diagnosis of a non-complement-mediated inherited renal disease (e.g., focal segmental glomerulosclerosis). 12. Drug exposure-related HUS is identified. 13. Patients in Cohort 1 have undergone plasma exchange / plasma infusion (PE / PI) for ≥28 days prior to the start of screening for the current TMA. 14. History of malignancy within 5 years of screening, except for nonmelanoma skin cancer or intraepithelial carcinoma of the cervix that has been treated and has no evidence of recurrence. 15. Bone marrow transplant (BMT) / hematopoietic stem cell transplant (HSCT) within 6 months immediately prior to the start of screening. 16. Genetic abnormalities in cobalamin C metabolism known to be associated with HUS. 17. Known systemic sclerosis (systemic scleroderma), systemic lupus erythematosus (SLE), or positive antiphospholipid antibodies or syndrome. 18. Chronic dialysis (defined as dialysis performed regularly as renal replacement therapy for end-stage renal disease). 19. Patients receiving chronic intravenous immunoglobulin (IVIg) within 8 weeks prior to screening, except for patients with an unrelated medical condition (e.g., hypogammaglobinemia) or chronic rituximab treatment within 12 weeks prior to screening. 20. Patients receiving other immunosuppressive therapy, such as steroids, mTORi (e.g., sirolimus, everolimus, etc.), or CNIs (e.g., cyclosporine, tacrolimus, etc.), are excluded unless this is part of an established post-transplant anti-rejection regimen, or the patient has identified anti-complement factor antibodies requiring immunosuppressive therapy, or steroids are being used for a condition other than aHUS (e.g., asthma). 21. Participation in another interventional therapeutic trial or use of any experimental treatment during the 30 days prior to starting study drug on Day 1 of this study, or for up to 5 half-lives of the study product, whichever is longer. 22. For patients in Cohort 1, history of use of any complement inhibitors. 23. For patients in Cohort 2, history of use of complement inhibitors other than eculizumab. 24. For patients in Cohort 2, abnormal TMA parameters (e.g., LDH ≥ ULNx1.5, platelet count < 150,000 / μL, or eGFR ≤ 30 mL / min / 1.73 m using the Schwartz formula) within 90 days prior to screening 2 ) was discovered. 25. Hypersensitivity to any component of the test drug, including hypersensitivity to murine proteins. 26. Any medical or psychiatric condition which, in the opinion of the Investigator or Sponsor, may increase risk to the patient from participation in the study or which may confound the outcome of the study. 27. Known or suspected drug or alcohol abuse or dependence within 1 year prior to screening. 28. Use of tranexamic acid within 7 days prior to screening is prohibited.
[0120] 1. Investigational Product, Dosage and Method of Administration Ravulizumab is a humanized anti-C5 monoclonal antibody, an IgG2 / 4 kappa immunoglobulin composed of two 448 amino acid heavy chains and two 214 amino acid light chains, with human constant regions and mouse complementarity determining regions grafted onto human framework light and heavy chain variable regions.
[0121] The ULTOMIRIS drug product is supplied for clinical trials as a sterile, preservative-free 10 mg / mL solution in single-use vials, diluted in commercially available saline (0.9% Sodium Chloride Injection, National Pharmacopoeia) and designed for infusion for administration via IV infusion. Additional information is provided in Table 2 and in the latest IB. [Table 2-1]
[0122] ULTOMIRIS will be packaged in United States Pharmacopeia (USP) / European Pharmacopeia (EP) Type 1 borosilicate glass vials and stoppered with butyl rubber stoppers with aluminum overseals and flip-off caps. Study drug will be provided in kits. ULTOMIRIS will be released to sites upon receipt of all required documentation as required by applicable regulations.
[0123] Upon arrival of the study drug kit at the study site, the pharmacist (or trained designee) will promptly remove the study drug kit from the shipping cooler and store it in its original box under refrigerated conditions at 2C-8C, protected from light. ULTOMIRIS is not frozen. Study drug will be stored in a secure, limited-access storage area with temperature monitored daily.
[0124] The mixed formulation is allowed to come to room temperature prior to administration. Materials are not heated other than by ambient temperature (e.g., using a microwave or other heat source).
[0125] ULTOMIRIS will not be administered as an IV push or bolus injection. Study drug infusions will be prepared using aseptic technique. The patient's required dose of ULTOMIRIS will be further diluted in commercially available saline (0.9% sodium chloride, national pharmacopoeia) in the amounts specified in Table 3. ULTOMIRIS mixture will be administered to the patient using an IV tubing administration set via an infusion pump. Use of a 0.2 micron filter for infusion is required. [Table 3-1] [Table 3-2]
[0126] Doses of study medication will be prepared and dispensed only by a pharmacist or medically qualified study personnel. Study medication will be dispensed only to enrolled patients who are identified as eligible to participate in the study. Once study medication is prepared for a patient, it will be administered only to that patient. Vials of study medication will be used once only, and any preparation remaining in the vial will not be used for another patient. Any drug remaining in the infusion tubing or infusion bag will not be used for another patient.
[0127] All clinical trial materials will be stored in a secure location and appropriately trained personnel will be assigned and deployed. Detailed records will be maintained of quantities of study product received, deployed, and discarded. Unless otherwise noted, empty and residual vials will be retained for inspection and accountability by study monitors before destruction or will be handled in accordance with the local pharmacy's standard operating procedures (SOPs) for clinical trial medications. To meet regulatory requirements for medication accountability, at the conclusion of the study, all remaining ULTOMIRIS inventory will be reconciled and destroyed or returned in accordance with applicable regulations.
[0128] For Cohort 1 and Cohort 2, a ravulizumab loading dose on day 1 and maintenance doses on day 15 and every 8 weeks (q8w) thereafter for patients weighing 20 kg or more, or every 4 weeks (q4w) thereafter for patients weighing less than 20 kg, will be administered by IV infusion. As shown in Table 3 below, doses are based on the patient's weight recorded on the dosing regimen determination date (if the dosing regimen date is the dosing date, weight is recorded prior to dosing).
[0129] During the initial evaluation period, changes in dosing regimen (dose level or dosing frequency [e.g., q4w vs. q8w]) are based on the patient's weight on the "Dosing Regimen Decision Date (Patients on q4w or q8w Schedule)" preceding the dosing date. Patients changing from q4w to q8w will receive their first q8w dose on the ULTOMIRIS dosing date after the "Dosing Regimen Decision Date (Patients on q4w or q8w Schedule)" ("ULTOMIRIS Dosing [Patients Who BW >20 kg]"). Patients changing from q8w to q4w will receive their first q4w dose on the ULTOMIRIS dosing date after the "Dosing Regimen Decision Date (Patients on q4w or q8w Schedule)" ("ULTOMIRIS Dosing [Patients Who BW <20 kg]").
[0130] During the extension period, the dose of ULTOMIRIS is based on the patient's weight on the preceding "Dosing Regimen Decision Date (Patients on q4w Schedule)" or "Dosing Regimen Decision Date (Patients on q8w Schedule)". Patients switching from q4w to q8w will receive their first q8w dose on the ULTOMIRIS administration date after the "Dosing Regimen Decision Date (Patients on q4w Schedule)" ("ULTOMIRIS Administration [Patients Who BW >20 kg]"). Patients switching from q8w to q4w will receive their first q4w dose on the ULTOMIRIS administration date 8 weeks after the "Dosing Regimen Decision Date (Patients on q8w Schedule)" ("ULTOMIRIS Administration [Patients Who BW <20 kg]").
[0131] 1.Endpoint: Efficacy evaluation Patients previously treated with eculizumab had stable TMA parameters at study enrollment, and therefore patients in Cohort 2 were excluded from the following efficacy assessments: complete TMA remission, time to complete TMA remission, status of complete TMA remission over time, and hemoglobin increase from baseline.
[0132] The primary efficacy endpoint for Cohort 1 was complete TMA remission during the 26-week initial evaluation period, evidenced by normalization of hematological parameters (platelet count and LDH) and ≥25% improvement from baseline in serum creatinine. Patients must meet all complete TMA remission criteria on two separate assessments obtained at least 4 weeks (28 days) apart, and any measurements in between.
[0133] Secondary efficacy endpoints for Cohort 1 were as follows, measured through 26 weeks and throughout the study: (1) requirement for dialysis; (2) time to complete TMA remission; (3) status of complete TMA remission over time; (4) change from baseline in eGFR, measured and from baseline; (5) CKD stage as assessed by eGFR at the selection date and classified as improvement, stable (no change), or worsening compared to baseline; (6) change from baseline in hematological parameters (platelets, LDH, hemoglobin); (7) increase in hemoglobin of ≥20 g / L from baseline observed at two separate assessments obtained at least 4 weeks (28 days) apart and at any measurement in between; and (8) change from baseline in QoL as measured by the Pediatric FACIT-Fatigue questionnaire (patients aged 5 years and older).
[0134] Secondary efficacy endpoints for Cohort 2 were as follows, measured up to 26 weeks and throughout the study: (1) need for dialysis; (2) change from baseline and actual in eGFR; (3) CKD stage as assessed by eGFR at the selection date and classified as improvement, stable (no change), or worsening compared to baseline; (4) change from baseline in hematological parameters (platelets, LDH, hemoglobin); and (5) change from baseline in QoL measured by the Pediatric FACIT-Fatigue questionnaire (patients aged 5 years and older).
[0135] The following PK / PD endpoints will be applied to Cohort 1 and Cohort 2: (1) change in serum ravulizumab concentrations over time, and (2) change in serum free C5 concentrations over time.
[0136] Biomarkers, genetic features and extrarenal signs or symptoms of aHUS are exploratory endpoints applied to cohort 1 and cohort 2. Exploratory biomarkers of PD efficacy may include, but are not limited to, changes from baseline in levels of markers of complement dysregulation (e.g., factor Ba), vascular inflammation (e.g., soluble tumor necrosis factor receptor 1 [sTNFR1]), endothelial activation / injury (e.g., soluble vascular adhesion molecule 1 [sVCAM-1], thrombomodulin), coagulation (e.g., D-dimer) and renal injury (e.g., cystatin C). Additional assessments may include measurements of urinary ravulizumab excretion, chicken red blood cell (cRBC) hemolysis, total C5, autoantibodies against complement proteins (e.g., anti-factor H).
[0137] Exploratory genetic characterization may be performed to investigate genetic variants in genes known to be associated with aHUS, as well as to identify novel genetic variants associated with aHUS, complement dysregulation, or ULTOMIRIS metabolism or efficacy. Patients (or legal guardians) may decline to provide a sample for exploratory genetic characterization and still participate in the study.
[0138] Investigators will assess extrarenal signs or symptoms of aHUS using clinical laboratory measurements, vital signs, and organ-specific examinations.
[0139] For Cohort 1 and Cohort 2, the long-term safety and tolerability of ULTOMIRIS will be assessed by physical examination, vital signs, physical growth (height, weight and head circumference [the latter only for patients aged 2 years and younger]), electrocardiogram (ECG), clinical laboratory assessments, and the occurrence of adverse events (AEs) and serious adverse events (SAEs). The proportion of patients who develop anti-drug antibodies (ADAs) will also be assessed.
[0140] 2.Statistical method Continuous variables will be summarized using descriptive statistics including number of observations and mean, standard deviation (SD) values, median, minimum, and maximum. Categorical variables will be summarized by frequency counts and percentages of patients. Analyses for cohort 1 and cohort 2 will be performed and reported separately. Analyses specific to cohort 1 are presented below. All other endpoints will be performed for both cohorts. Table summaries will not include direct comparisons between cohort 1 and cohort 2.
[0141] Interim Clinical Study Reports (CSRs) will be prepared when 12–14 complement inhibitor-naïve patients (i.e., cohort 1) have completed or withdrawn from the 26-week initial evaluation period. Additional interim CSRs will be prepared when all study patients have completed or withdrawn from the 26-week initial evaluation period. Each interim CSR will include efficacy, safety and PK / PD analyses. A final CSR summarizing long-term efficacy, safety, and PK, PD will be prepared at study completion. Any exploratory data available will be summarized after study completion but may not be included in the CSR. All data collected will be presented using summary tables, figures and data listings. Planned summaries will be presented overall and by age group, if applicable.
[0142] Efficacy analysis will be performed on the Full Analysis Set (FAS). Analysis of the FAS will be the primary analysis. The FAS for cohort 1 will be based on a modified intent to treat (mITT) approach. With this approach, patient eligibility may be confirmed after administration of the study drug. This applies in particular to inclusion criterion number 2c (which must be confirmed via a central clinical laboratory), exclusion criterion number 1 (which may be confirmed via a central or local clinical laboratory), and exclusion criterion number 2 (which may be confirmed via a central or local clinical laboratory). Based on the above, the FAS will include all patients who received at least one dose of ravulizumab, underwent at least one post-baseline efficacy assessment, and met all of the following criteria (criteria that, if not met, would trigger the possibility of patient discontinuation and replacement): (1) patients who met inclusion criterion number 2c, (2) patients who met exclusion criterion number 1, and (3) patients who met exclusion criterion number 2. The FAS for Cohort 2 includes all patients who received at least one dose of ULTOMIRIS and had at least one post-baseline efficacy assessment. The FAS will be adjudicated prior to database lock and prior to database snapshot for analyses conducted at the end of the 26-week initial evaluation period.
[0143] The primary efficacy endpoint is complete TMA remission during the 26-week initial evaluation period. The primary analysis will consist of estimating the proportion of complete TMA remission among ULTOMIRIS-treated patients. This will be performed by calculating the point estimate and 95% confidence interval (CI) of the proportion of complete TMA remission among ULTOMIRIS-treated patients. CIs will be based on exact confidence limits using the Clopper-Pearson method. This analysis will be performed on cohort 1 only.
[0144] For the secondary efficacy endpoint time to complete TMA remission, Kaplan-Meier cumulative distribution curves will be constructed with two-sided 95% CIs. The corresponding summary table shows cumulative distribution function (CDF) estimates, the number of patients at risk, the number of patients in remission, and the number of patients censored at each post-baseline time point. The table also shows the second quartile, median, and third quartile for time to complete remission with the corresponding two-sided 95% CIs. This analysis will be performed for cohort 1 only.
[0145] Complete TMA remission will also be summarized over time by showing the number and percentage of remitters for each time point after baseline with two-sided 95% CI. Using a similar method, the number and percentage of patients with a hemoglobin increase of ≥20 g / L from baseline on two separate assessments obtained at least 4 weeks (28 days) apart, and any measurement in between, will be summarized. This analysis will be performed for Cohort 1 only.
[0146] Renal function (need for dialysis, eGFR, CKD stage) and hematological parameters (platelets, LDH, hemoglobin) will be summarized at baseline and at each post-baseline time point. These analyses will be performed for both cohort 1 and cohort 2. Descriptive statistics for continuous variables (eGFR, platelets, LDH, hemoglobin) will be used to summarize observed values and changes from baseline. A mixed model for repeated measures (MMRM) including fixed categorical effects of visit and fixed continuous effects of baseline values for specific studies as covariates may be fitted to verify whether changes are different from zero at each time point. Need for dialysis and CKD stage will be summarized over time. Need for dialysis will be summarized by showing the number and proportion of patients on dialysis and not on dialysis at each time point among patients receiving dialysis within 5 days before starting ravulizumab treatment. Two-sided 95% CIs for proportion on dialysis are shown. CKD stage is summarized over time by showing the number and proportion of patients who improved (excluding patients with stage 1 at baseline who cannot improve), worsened (excluding patients with stage 5 at baseline who cannot worsen), and remained the same compared to baseline CKD stage, with stage 5 being the worst category and stage 1 being the best category. Two-sided 95% CIs for proportions in each category are shown.
[0147] Quality of life will be assessed in patients aged 5 years and older with the FACIT-Fatigue questionnaire for children (patient-reported for patients aged 8 years and older at enrollment; caregiver-reported or caregiver-assisted reporting for patients aged 5-8 years at enrollment). This measure will be summarized at baseline and at each post-baseline time point using descriptive statistics for continuous variables for actual values and for the change from baseline. MMRMs may be fitted, including fixed categorical effects of visit and fixed continuous effects of study baseline as covariates, to test whether the change differs from zero at each time point. These analyses will be performed for both cohort 1 and cohort 2. Analyses will be differentiated between patients aged 5-8 years at enrollment (caregiver-reported or caregiver-assisted reporting) and patients aged 8 years and older at enrollment (patient-reported).
[0148] Safety analyses will be performed for both Cohort 1 and Cohort 2 in the Safety Set, defined as all patients who received at least one dose of ULTOMIRIS. The occurrence of treatment-emergent adverse events (TEAEs) and SAEs will be summarized overall, by severity, and by relationship to treatment by system organ class (SOC) and preferred term (PT). Observed values and changes from baseline (last assessment pre-ULTOMIRIS) in ECG, vital signs, and laboratory assessments, and the presence of ADAs will be summarized. Shifts from baseline in laboratory assessments will be summarized for all study visits. These analyses will be performed for both Cohort 1 and Cohort 2.
[0149] Meningococcal infection is an important risk identified in this study.
[0150] An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product that does not necessarily have a causal relationship to this treatment. Thus, an AE can be any undesirable or unintended sign (e.g., abnormal clinical laboratory findings), symptom, or disease that is temporally associated with the use of a medicinal product, whether or not it is considered related to that medicinal product.
[0151] Situations in which unfavorable medical events did not occur (e.g., hospitalization for surgery scheduled before the start of the study, hospitalization for social reasons and / or convenience), and expected day-to-day fluctuations of a pre-existing disease or condition that was present or detected at the start of the study and does not worsen, are not AEs.
[0152] The severity of AEs is graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or later. A grading (severity) scale is provided for each AE term. Each CTCAE term is a Lowest Level Term (LLT) based on the Medical Dictionary for Clinical Practice (MedDRA®). Each LLT is coded to a MedDRA Preferred Term (PT). Grade refers to the severity of the AE. The CTCAE assigns a grade from 1 to 5 and provides a specific clinical description of the severity of each AE (Table 4). [Table 4]
[0153] Any changes in the severity of an AE are recorded based on specific guidelines in the eCRF implementation guidelines. A distinction is made between severity and seriousness. Severity describes the intensity of the AE, while the term seriousness refers to an AE that meets certain criteria for a serious adverse event (SAE).
[0154] For all adverse events (both serious and nonserious), the investigator must provide a causality assessment (not causal, unlikely, possible, probable, or definite) based on the investigator's medical judgment and any symptoms observed in relation to the event (Table 5). This assessment will be recorded on the eCRF and any additional forms, as appropriate. [Table 5-1] [Table 5-2]
[0155] A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening (i.e., the patient is in jeopardy of death at the time of the event), requires hospitalization or prolonged hospitalization, results in persistent or significant impairment / incapacity, or results in a congenital abnormality / birth defect.
[0156] Significant medical events that do not result in death, but may be immediately life-threatening or require hospitalization, may be considered serious adverse events if, based on sound medical judgment, they may be patient-threatening or may require intervention to avoid one of the outcomes listed above.
[0157] Suspected unexpected serious adverse reactions (SUSARs) are serious events not listed in the IB and identified by the investigator as related to the investigational product or procedure.
[0158] All SAEs will be recorded regardless of the investigator's assessment of causality. There is no time limit for reporting SAEs that are considered to be causally related to the study drug. Investigators are free to report SAEs at any time, regardless of whether they are causally related.
[0159] For all SAEs, the investigator must provide the following: appropriate and requested follow-up information, causality of the SAE, treatment of the SAE / intervention for the SAE, outcome of the SAE, and supporting medical records and laboratory / diagnostic information.
[0160] Pregnancy data will be collected for all patients and female spouses / partners of male patients during the study. Exposure during pregnancy (also called intrauterine exposure) can be the result of either maternal exposure or the transmission of drug via semen following paternal exposure. Pregnancy itself is not considered an adverse event unless there is suspicion that the investigational drug may be interfering with the effectiveness of contraceptives. However, pregnancy complications and abnormal pregnancy outcomes are AEs and may meet the criteria for an SAE (e.g., ectopic pregnancy, spontaneous abortion, intrauterine fetal death, neonatal death, or congenital anomaly). Uncomplicated elective termination of pregnancy should not be reported as an AE.
[0161] Small PK and PD (serum free C5) samples will be collected throughout the study. Individual serum concentration data from the FAS and for all patients with evaluable PK data will be used to derive ULTOMIRIS PK parameters. These analyses will be performed for both Cohort 1 and Cohort 2. Mean serum concentration-time profile graphs will be generated. Individual patient serum concentration-time profile graphs may also be provided. Actual dose administration and sampling times will be used for all calculations. Descriptive statistics will be calculated as appropriate for serum concentration data at each sampling time. Population-PK assessments may be considered using data from this study or combined with data from other studies.
[0162] PD analyses will be performed for all patients from the Cohort 1 FAS and Cohort 2 FAS with evaluable PD data. The PD effect of ULTOMIRIS will be evaluated by assessing absolute, change from baseline, and percentage change from baseline in serum free C5 serum concentrations over time, as appropriate. Descriptive statistics will be calculated for PD data at each sampling time, as appropriate. PK / PD association assessments may be investigated using data from this study or combined with data from other studies.
[0163] Exploratory analyses may be performed on both cohort 1 and cohort 2 to evaluate changes from baseline in markers that may include, but are not limited to, markers of complement dysregulation (e.g., factor Ba), vascular inflammation (e.g., sTNFR1), endothelial activation / injury (e.g., sVCAM-1, thrombomodulin), coagulation (e.g., D-dimer), and renal injury (e.g., cystatin C). Additional analyses may include evaluation of urinary ravulizumab excretion, cRBC hemolysis, total C5, and autoantibodies against complement proteins (e.g., anti-factor H).
[0164] Exploratory genetic characterization may be performed on both Cohort 1 and Cohort 2 to investigate genetic variants in genes known to be associated with aHUS, as well as to identify novel genetic variants associated with aHUS, complement dysregulation, or ULTOMIRIS metabolism or efficacy. Patients (or legal guardians) may decline to provide a sample for exploratory genetic characterization and still participate in the study.
[0165] Extrarenal signs or symptoms of aHUS will be summarized at baseline and at each post-baseline assessment by showing the number and percentage of patients with specific symptoms. This analysis will be performed for both Cohort 1 and Cohort 2.
[0166] Example 2: Interim Data from a Phase III, Open-Label, Multicenter Study in Complement Inhibitor-Naive Children and Adolescents with aHUS The following is a summary of interim data from a single-arm, open-label, predictive study of ravulizumab in children and adolescents with aHUS conducted substantially according to the protocol described above in Example 1. Results are included through the end of the 26-week initial evaluation period or through study discontinuation for the first 16 patients enrolled in the study (all of whom were Cohort 1 patients). The study design is shown in Figure 1.
[0167] The objective of this study was to evaluate the efficacy of ravulizumab in inhibiting complement-mediated thrombotic microangiopathy (TMA), characterized by thrombocytopenia, hemolysis, and renal dysfunction, in complement inhibitor-naïve pediatric patients with aHUS. The primary endpoint was complete remission of TMA within the initial evaluation period (26 weeks).
[0168] A. Analyzed Dataset Four patients were included in each of the four age groups: (A) birth to <2 years, (B) 2 to <6 years, (C) 6 to <12 years, and (D) 12 to <18 years. Sixteen subjects were enrolled and received at least one dose (included in the safety analysis set). Two subjects were enrolled and replaced (disqualified after first dose and discontinued). Fourteen subjects were included in the full analysis set, with one subject discontinued on day 21 due to an adverse event. There was 100% compliance with study treatment. A summary of patient disposition is provided in Figure 2 and further described in Table 6. Baseline demographics (Table 7) and baseline disease characteristics (Table 8) are provided below. [Table 6] [Table 7-1] [Table 7-2] [Table 8-1] [Table 8-2]
[0169] The first 16 patients enrolled and treated in cohort 1 are included in the safety analysis set (Table 9). Two patients were excluded from the full analysis set. Both of these patients were treated based on validation of inclusion and exclusion criteria by local laboratory results and were subsequently discontinued for not meeting specific eligibility criteria once all central laboratory results for Screening / Day 1 were available. All 14 patients in the full analysis set were included in the per-protocol population. [Table 9]
[0170] For the 14 patients in the full analysis set, the mean age at first aHUS symptom was 4.94 years (Table). At baseline (within 5 days of first dose of study drug), 5 of 14 patients (35.7%) in the FAS received renal dialysis related to renal failure caused by aHUS. One patient (7.1%) in the full analysis set received a renal transplant related to aHUS before study entry. The majority of patients evaluated at baseline (11 of 16 patients) had CKD stage 4 or 5, with 5 patients (35.7%) in stage 5. [Table 10-1] [Table 10-2]
[0171] The majority of patients (10 / 14, 71.4%) had pretreatment extrarenal signs or symptoms of aHUS at baseline (Table). [Table 11-1] [Table 11-2]
[0172] All 14 patients in the full analysis set had a hospitalization and / or emergency room visit due to aHUS prior to screening, as shown in Table 12. Prior to screening, 6 (42.9%) patients had received ICU-level care during their aHUS hospitalization, with a mean (SD) duration of ICU stay of 10.0 days (18.63 days). At the time of first dose of study medication, 13 / 14 (92.9%) patients had been hospitalized for aHUS. [Table 12-1] [Table 12-2]
[0173] All 16 patients had a history of previous medications. The most commonly reported (≥15% of patients) groups of medications included pneumococcal vaccines (87.5%), Hib vaccines (75%), meningococcal vaccines (50.0%), sulfonamides (43.8%), solutions affecting electrolyte balance (37.5%), combined bacterial and viral vaccines (31.3%), benzodiazepine derivatives (31.3%), blood substitutes and plasma protein fractions (31.3%), electrolyte solutions (31.3%), other general anesthetics (31.3%), and anilides (25.0%). 0%), dihydropyridine derivatives (25.0%), H2-receptor antagonists (25.0%), proton pump inhibitors (25.0%), alpha and beta blockers (18.8%), glucocorticoids (18.8%), opioid anesthetics (18.8%), other antianemic agents (18.8%), potassium (18.8%), substituted alkylamines (18.8%), third-generation cephalosporins (18.8%), and other quaternary ammonium compounds (18.8%).
[0174] Prior to the study, 87.5% of patients had received a non-pharmacological or medical treatment within 28 days of screening. In total, 31.3% of patients had received pre-treatment plasma exchange / plasma infusion (PE / PI) associated with a current TMA and 37.5% had received renal dialysis within 56 days prior to the first dose of study drug.
[0175] All patients were taking at least one concomitant medication. The most commonly reported (≥15% of patients) concomitant medication classes were extended-spectrum penicillins (75.0%), nylides (68.8%), dihydropyridine derivatives (68.8%), meningococcal vaccines (68.8%), electrolyte solutions (62.5%), osmotic laxatives (56.3%), serotonin antagonists (50.0%), benzodiazepine derivatives (43.8%), electrolyte solutions (43.8%), and enemas (43. .8%), other general anesthetics (43.8%), simple ACE inhibitors (37.5%), glucocorticoids (37.5%), hydrazinophthalazine derivatives (37.5%), selective immunosuppressants (37.5%), simple sulfonamides (37.5%), second generation cephalosporins (31.3%), H2-receptor antagonists (31.3%), heparin group (31.3%), other antianemic agents (31.3%), proton pump inhibitors (31.3%), and ketamine-releasing agents (31.3%). inhibitors (31.3%), third-generation cephalosporins (31.3%), vitamin D and analogues (31.3%), alpha and beta blockers (25.0%), topical anesthetics (25.0%), oral divalent iron preparations (25.0%), mucolytics (25.0%), natural opium alkaloids (25.0%), phenylpiperidine derivatives (25.0%), pneumococcal vaccines (25.0%), selective beta-2 receptor agonists ( 25.0%), amides (18.8%), simple angiotensin II antagonists (18.8%), antibiotics (18.8%), beta-lactamase-susceptible penicillins (18.8%), agents for the treatment of hyperkalemia and hyperphosphatemia (18.8%), fluoroquinolones (18.8%), influenza vaccines (18.8%), parenteral nutrition solutions (18.8%), and magnesium (18.8%).
[0176] During the study, 93.8% of patients received non-pharmacological or medical treatment. No patients received PE / PI.
[0177] For the 14 patients in the full analysis set, the mean (SD) treatment duration was 24.51 (6.196) weeks, and all patients received all scheduled doses during the initial evaluation period. One patient discontinued study drug and was considered 100% compliant because he had not missed any doses prior to the discontinuation date. Treatment interruption due to adverse events was reported in one patient.
[0178] B. Efficacy Results Regarding efficacy, the primary efficacy endpoint of complete TMA remission showed a remission rate of 71.4% (10 / 14) with 95% CI=(0.419, 0.916) during the initial evaluation period of 26 weeks, as shown in Figure 3 and Table 13. The criteria for complete TMA remission were (1) normalization of platelet count, (2) normalization of LDH, and (3) ≥25% improvement from baseline in serum creatinine. The components of complete TMA remission, as well as other secondary efficacy endpoints, also showed results consistent with cTMA remission, as shown in Figure 4. [Table 13]
[0179] Patients had to meet all complete TMA remission criteria on two separate assessments obtained at least 4 weeks (28 days) apart, and any measurements in between. Hematologic normalization included normalization of platelet count and normalization of LDH. Platelet values obtained from the date of platelet transfusion through 3 days after transfusion were excluded from all analyses. All serum creatinine values obtained while the patient was on dialysis were excluded from all analyses. If the patient was on dialysis at baseline, the first valid creatinine value used as baseline was the first assessment ≥6 days after dialysis. If the patient was on dialysis for the entire 26-week initial assessment period, no baseline creatinine was calculated.
[0180] Except for one patient who withdrew from the study after two doses of ULTOMIRIS, all 13 patients achieved normalization of platelet counts during the initial evaluation period, as shown in Table 13. During the initial evaluation period, 12 patients achieved normalization of LDH and 11 patients achieved improvement in renal function (defined as a 25% decrease from baseline in serum creatinine).
[0181] Of the four patients who did not achieve complete TMA remission, two patients achieved normalization of LDH and platelet counts and one patient achieved normalization of platelet counts and improvement in renal function during the initial evaluation period. The one patient who did not improve in any of the complete TMA remission components withdrew from the study due to an adverse event after receiving two doses of study drug.
[0182] A separate sensitivity analysis was performed using a modified version of complete TMA remission. This modification was applied only to patients on dialysis at baseline. Regarding the modified complete TMA remission analysis, complete TMA remission was observed in the majority of these patients (71.4% [95% CI: 41.9%, 91.6%) in the FAS and PP populations.
[0183] The median time to complete TMA remission during the early evaluation period was 30 days, occurring as quickly as 15 days after the first dose of ULTOMIRIS, as shown in Figure 3. As shown in Figure 5, the latest remission was observed on day 88, with all cTMA responses sustained through day 183. Patients who did not achieve remission were censored at the date of their last visit or study discontinuation. One patient was censored on day 21, one on day 181, and two on day 183.
[0184] All 10 patients who achieved complete TMA remission remained in that state by Day 85, as shown in Table 14 and Figure 6. Nine of these remitters maintained complete TMA remission from the first time they achieved it through the end of the 26-week initial evaluation period. One patient achieved complete TMA remission on Day 15 and continued to meet remission criteria through the end of the 26-week initial evaluation period, except for Visit 1 (Day 71). [Table 14]
[0185] With the exception of one patient who withdrew from the study after two doses of ULTOMIRIS, all 13 remaining patients in the FAS achieved normalization of platelet counts as shown in Table 6. Platelet count normalization was achieved after the first dose of study drug (i.e., day 15) in 12 patients, day 8 in 9 patients, and day 15 in 3 patients. The latest remission was observed on day 71 (n=1). When platelet count normalization was achieved, all patients maintained normalization except for one patient who did not meet this criterion at one time point. That patient then normalized platelet counts again during the remainder of the initial evaluation period.
[0186] Of the 12 patients who achieved LDH normalization, 4 patients achieved it on day 15, as shown in Figure 6. The latest remission was observed on day 99 (n=1). When LDH normalization was achieved, all patients sustained normalization except for two patients who did not meet this criterion at one time point (one at day 183 and one transiently at day 71, who then normalized LDH counts again for the remainder of the initial evaluation period).
[0187] Of the 11 patients in the full analysis set who achieved renal improvement, as shown in Figure 6, 6 patients achieved renal improvement after the first dose of study drug (i.e., by day 15), 5 patients achieved renal improvement by day 8, and 1 patient achieved remission by day 15. The latest remission was observed on day 57 (n=1). All patients who met the component criteria for renal improvement maintained this remission throughout the initial evaluation period.
[0188] Hematological normalization included normalization of platelet count and normalization of LDH. During the initial evaluation period, hematological normalization was observed in 12 of 14 patients (85.7% [95% CI: 57.2%, 98.2%]), as shown in Table 15 and Figure 6.
[0189] Overall, patients in the full analysis set showed improvement in all hematological TMA parameters (platelets, LDH and hemoglobin) during the initial evaluation period, with improvements in platelets and LDH observed from day 8 and improvements in hemoglobin observed from day 22.
[0190] The mean (SD) change from baseline in platelet count was 238.08 (154.402) on day 8. This mean increase was sustained over the initial evaluation period (Figure 7).
[0191] The mean (SD) change from baseline in LDH was −1330.61 (952.371) at day 8 and increased to −2111.88 (1350.886) at day 29. This mean decrease was sustained over the initial evaluation period (Figure 8).
[0192] The mean (SD) change from baseline in hemoglobin was 10.79 (16.120) on day 15 and increased to 36.13 (21.597) on day 43. This mean increase was sustained over the initial evaluation period (Figure 9).
[0193] During the initial evaluation period, 12 of 14 patients in the full analysis set [85.7% (95% CI: 57.2%, 98.2%)] had a hemoglobin increase of 20 g / L or more compared to baseline with a confirmed result (e.g., hemoglobin response). Of 13 patients who completed 26 weeks of ULTOMIRIS treatment, 12 patients had a hemoglobin response at Day 99, as shown in Table 15. [Table 15-1] [Table 15-2]
[0194] Baseline was defined as the mean of values from assessments performed before the first dose of study drug (which could include results from screening and Day 1 visits). Patients were included in analyses for a particular post-baseline time point if confirmation of the result at that time point was available. Hemoglobin values obtained from the date of transfusion of either whole blood or packed red blood cells up to 7 days after transfusion were excluded from all analyses.
[0195] Figure 10 shows the dialysis status over time for patients. Day 1 is the day of treatment initiation. Five days before the treatment initiation date was used as the starting time point. As shown in Figure 10, of the five patients on dialysis at baseline, four stopped dialysis within 29 days after exposure to ravulizumab. No new patients started dialysis after treatment initiation.
[0196] Figure 11 shows the change in estimated glomerular filtration rate (EGFR) from baseline, including the mean change and 95% confidence interval. Baseline was defined as the mean of values obtained from assessments performed before the first dose of study drug (which could include results from screening and Day 1 visits). For eGFR, a mean of 10 mL / min / 1.73 m was used for patients requiring dialysis for acute kidney injury. 2were assigned to each patient. A mixed model for repeated measures (MMRM) was used. Covariates included a fixed categorical effect for visit and a fixed continuous effect for baseline. Within-patient error was modeled using a Toeplitz covariance structure. Observed values: mean ± 95% CI. Model-based values: mean ± 95% CI.
[0197] Renal function, as assessed by mean (SD) eGFR, was 28.4 (23.11) mL / min / 1.73 m at baseline. 2 to 108.0 (63.21) mL / min / 1.73 m at the end of the initial evaluation period. 2 The results of the repeated measures mixed model (MMRM) statistical analysis of the change from baseline in eGFR showed improvement within 29 days of starting ULTOMIRIS treatment (Figure 11). One patient had a history of kidney transplantation. This patient also had an improvement in eGFR compared to baseline (22.0-29.0 mL / min / 1.73 m2) during the initial evaluation period.
[0198] As shown in Table 16, the majority of patients (11 of 14 patients) evaluated at baseline had chronic kidney disease (CKD) stage 4 or 5, with 5 patients (35.7%) in stage 5. All but 2 patients improved their CKD stage (e.g., shifted from baseline to a lower CKD stage by the end of the initial evaluation period (day 183)). This shift was significant, with 9 patients improving by 2 or more stages. [Table 16]
[0199] Bolded values in Table 16 indicate improvement compared to baseline, and underlined values indicate deterioration compared to baseline. Baseline was derived based on the last eGFR available before treatment initiation. Patients with both baseline and at least one value at the post-baseline visit were included in the summary. Percentages were based on the total number of patients with no missing data at both baseline and post-baseline visits. CKD stage is classified based on the National Kidney Foundation Chronic Kidney Disease Stage. CKD stages: Stage 1 = eGFR ≥ 90 (normal); Stage 2 = eGFR 60-89; Stage 3A = eGFR 45-59; Stage 3B = eGFR 30-44; Stage 4 = eGFR 15-29; Stage 5: eGFR < 15 (including dialysis: end stage).
[0200] As shown in Table 17, at the end of the initial evaluation period, 11 of 13 patients (84.6%) had an improvement in CKD stage compared to baseline. Of these patients, 3 had an improvement of 5 stages, 4 had an improvement of 4 stages, 3 had an improvement of 2 stages, and 1 had an improvement of 1 stage.
[0201] Two patients did not experience improvement in CKD stage score during the initial evaluation period. One of these patients had a history of kidney transplantation before the study. No patients experienced a worsening of CKD stage during the initial evaluation period. [Table 17-1] [Table 17-2]
[0202] For eight treated patients over 5 years of age, quality of life (QoL) was assessed using the Pediatric FACIT-Fatigue questionnaire. Baseline was taken from the value on day 1. The Pediatric FACIT-Fatigue questionnaire was used. The Pediatric FACIT-Fatigue questionnaire at baseline and each post-dose time point was scored using a standard scoring algorithm. A repeated measures mixed model was used with fixed categorical effects of visit and fixed continuous effect of baseline value as covariates. Within-patient error was modeled using an unstructured covariance structure. FACIT scores ranged from 0 to 52, with higher scores indicating reduced fatigue. Actual values: mean ± 95% confidence interval (CI). Model-based values: mean ± 95% CI.
[0203] During the initial evaluation period, these eight patients had a mean (SD) improvement of 18.91 (14.988) in the Pediatric FACIT-Fatigue score compared to baseline, as shown in Figure 12. Three of the eight patients (37.5%) had a three-point improvement in the FACIT-Fatigue total score from baseline to day 8, seven (87.5%) patients had a three-point improvement from baseline to day 29, and all eight patients had a three-point improvement from baseline to day 71.
[0204] C. Efficacy Conclusions Ten of 14 patients (71.4%) (95% CI: 41.9%, 91.6%) in the FAS achieved the primary efficacy endpoint of complete TMA remission during the 26-week initial evaluation period. Thirteen of 14 patients in the FAS achieved normalization of platelet counts during the initial evaluation period. Twelve patients achieved normalization of LDH and 11 patients achieved improvement in renal function (defined as a 25% reduction from baseline in serum creatinine) during the initial evaluation period.
[0205] Secondary endpoint results included: The median time to complete TMA remission was 30 days, with the earliest remission occurring by 15 days after the first dose of ULTOMIRIS. For the 10 patients who achieved complete TMA remission, these remissions were sustained through the end of the 26-week initial evaluation period.
[0206] Hematological normalization, defined as normalization of both LDH and platelets, was observed in 12 of 14 patients [85.7% (95% CI: 57.2%, 98.2%)].
[0207] Of 14 patients in the full analysis set, 12 [85.7% (95% CI: 57.2%, 98.2%)] had a hemoglobin increase of ≥20 g / L with a confirmed result compared with baseline.
[0208] Of the five patients receiving dialysis at baseline, dialysis was discontinued in four. All four of these patients discontinued dialysis within 29 days of exposure to ULTOMIRIS. No patients initiated dialysis after initiating treatment with ULTOMIRIS.
[0209] Renal function, as assessed by eGFR, averaged 28.4 mL / min / 1.73 m at baseline. 2 to 108.0 mL / min / 1.73 m at the end of the initial evaluation period. 2 The majority of patients had at least one stage improvement in CKD compared with baseline.
[0210] Of 8 patients (e.g., patients >5 years of age), 3 (37.5%) had an improvement of at least 3 points in FACIT-Fatigue total score from baseline to day 8, 7 (87.5%) patients had an improvement of at least 3 points from baseline to day 29, and all 8 patients had an improvement of at least 3 points from baseline to day 71.
[0211] D. Pharmacokinetic and Pharmacological Results All patients in the full analysis set were included in the PK / PD analysis set. Mean (SD) ravulizumab serum concentrations are shown in Figure 13, comparing dosing intervals (e.g., q4w and q8w) versus time profile (linear scale).
[0212] Pharmacokinetic parameters of ULTOMIRIS are summarized by dosing interval in Tables 18 and 19 for the loading dose and last maintenance dose, respectively. Mean (SD) C max were 656.4 (250.3) and 599.8 (103.8) μg / mL in the q4w and q8w dosing interval groups, respectively, and C trough The mean (SD) Cs after the last maintenance dose were 240.7 (125.4) and 185.6 (30.7) μg / mL, respectively. max were 1466.6 (554.4) and 1863.3 (284.6) μg / mL in the q4w and q8w dosing interval groups, respectively, and C trough were 682.9 (315.1) and 549.3 (187.4) μg / mL, respectively. Exposures in patients weighing <20 kg (q4w) and those weighing ≥20 kg (q8w) were similar. [Table 1-2] [Table 2-2] [Table 2-3]
[0213] The final maintenance dose was administered on day 155 for those under 20 kg and on day 127 for those ≥20 kg.
[0214] Noncompartmental PK parameters following the final maintenance dose of ULTOMIRIS are shown by dosing interval in Table 20. [Table 20]
[0215] As shown in Table 21, steady state was achieved after weight-based maintenance doses of ravulizumab q4w and q8w. [Table 21-1] [Table 21-2]
[0216] Figure 14 shows box plots of serum free C5 concentrations versus time profiles by dosing interval. After weight-based dosing, ravulizumab treatment produced immediate and complete terminal complement inhibition (free C5 <0.5 μg / mL) that was sustained throughout the entire treatment period at all time points in all patients, except for one patient in the 5 kg to <10 kg weight group on day 15.
[0217] A prespecified initial analysis of PK / PD data in nine patients (CPR-0019.00) was performed to evaluate the appropriateness of pediatric dosing. Modeling and simulation results supported all pediatric dosing except for the loading dose in patients weighing ≥ 5 kg and < 10 kg. Therefore, in this weight group, the loading dose was increased from 300 mg to 600 mg (with no change to the maintenance dose of 300 mg q4w).
[0218] Mean total serum C5 concentrations (95% CI) and time profiles are shown by weight-based dosing regimen in Figure 15. Rates and magnitudes of change in serum total C5 were similar between groups.
[0219] E. Pharmacokinetic and Pharmacological Conclusions Following weight-based dosing of ULTOMIRIS, steady state was achieved for both dosing intervals and across all pediatric patients.
[0220] Immediate and complete terminal complement inhibition (defined as free C5<0.5) was achieved and sustained at all time points in all patients throughout the entire treatment period, except for one patient on day 15.
[0221] Based on initial protocol-specific PK / PD analyses performed to assess appropriateness of pediatric dosing, the loading dose was increased from 300 mg to 600 mg in patients weighing 5 kg to less than 10 kg. The dosing regimen in all other pediatric weight groups is appropriate.
[0222] F. Safety ULTOMIRIS exposure, including follow-up period, treatment period, and number of doses per patient, is summarized in Table 22. All patients received all planned doses according to the protocol-defined visit schedule and all doses at each visit during the initial evaluation period, except for three patients who withdrew from the study before Day 183. A change in dosing regimen was made for one patient, based on the patient's weight; the patient's weight increased to 20.4 kg on Day 113 (the dosing regimen decision day).
[0223] The median treatment duration was 26.14 weeks (range, 1-26.6 weeks), and all patients were compliant with treatment. Two patients weighing ≥ 5 kg and < 10 kg received a loading dose of 300 mg instead of 600 mg because they were enrolled before the protocol amendment became effective. [Table 22]
[0224] Percentages are based on the number of patients with no missing data in each group. Patients received a weight-based loading dose of ULTOMIRIS on day 1 and weight-based maintenance treatment on day 15 and q8w thereafter for patients weighing ≥20 kg or q4w thereafter for patients weighing <20 kg, for a total of 26 weeks of treatment. Weight-based dosing is based on the patient's weight recorded on the dosing regimen determination date. Dosing on day 183 represents the start of the extension period and is not included in these calculations.
[0225] ULTOMIRIS exposure, including duration of follow-up, duration of treatment, and number of doses per patient, is summarized in Table 22. All patients received all planned doses according to the protocol-defined visit schedule and all doses at each visit during the initial evaluation period, except for three patients who withdrew from the study before Day 183. A change in dosing regimen was made for one patient, based on the patient's weight; the patient's weight increased to 20.4 kg on Day 113 (the day of dosing regimen determination).
[0226] The median treatment duration was 26.14 weeks (range, 1-26.6 weeks), and all patients were compliant with treatment. Two patients weighing ≥ 5 kg and < 10 kg were given a loading dose of 300 mg instead of 600 mg because they were enrolled before the protocol amendment became effective.
[0227] During the initial evaluation period, 15 (93.8%) patients experienced at least one adverse event (162 events), as shown in Table 23. Eight (50%) patients reported adverse events that were assessed by the investigator as related to study drug.
[0228] The majority of patients experienced adverse events of grade 1 or grade 2 severity. Three (18.8%) patients experienced adverse events of grade 3 severity. One patient in the 6-18 year old group experienced an adverse event of grade 4 severity (neutropenia).
[0229] Eight patients (50%) experienced serious adverse events during the pre-treatment period. One patient (in the <6 year old group) withdrew from the study due to an SAE (hypertensive crisis and anemia) during the pre-treatment period.
[0230] Three patients experienced non-serious AEs during infusion of study drug (two hypertension, one dizziness). One patient's hypertension (day 15) was grade 2 in severity and treatment was interrupted for 10 minutes. The infusion was then resumed and the full dose was completed. As of the data cutoff date for this report, the AE was resolved. The other two AEs were grade 1 in severity, did not require interruption of the infusion, and resolved during the initial evaluation period.
[0231] No deaths were reported. No meningococcal infections were reported. [Table 23-1] [Table 23-2]
[0232] The most frequently reported AE was pyrexia [five patients (31.3%)], which was grade 1 or grade 2 in severity in all five patients and did not occur during study drug administration (see Table 24). Other events reported by three or more patients (18.8%) were pyrexia, constipation, vomiting, hypertension, headache, diarrhea, and nasopharyngitis. [Table 24-1] [Table 24-2]
[0233] During the initial evaluation period, AEs assessed by the investigator as related to study drug were reported by eight patients (50%). Two or more patients did not have a preferred term for the related AE.
[0234] During the initial evaluation period, the majority of patients experienced AEs that were grade 1 (four patients [25%]) or grade 2 (eight patients [50%]) in severity. Three patients (18.8%) experienced grade 3 events that were reported as SAEs.
[0235] One patient experienced a grade 4 AE of neutropenia that did not require specific treatment or interruption or discontinuation of study drug, and this patient also experienced a grade 3 AE of pleural effusion that resolved within 9 days.
[0236] During the initial evaluation period, eight patients (50.0%) experienced SAEs, as shown in Table 25. Infectious and disseminating SAEs were the most commonly reported in the system organ class (SOC) (four patients [25.0%]), followed by gastrointestinal (three patients [18.8%]) and vascular (two patients [12.5%]) SOCs. With the exception of abdominal pain, which was reported in two patients (12.5%), other SAEs were reported in one or fewer patients. A summary of the SAEs is shown in Table 26. [Table 25] [Table 26-1] [Table 26-2]
[0237] Anemia and hypertensive crisis led to discontinuation of study drug and withdrawal from the study in one patient.
[0238] All SAEs resolved during the initial evaluation period, except for cytomegalovirus enteritis, which was reported as ongoing at the time of data cutoff.
[0239] During the initial evaluation period, one patient (1.8 years, weight 9 kg) experienced adverse events (hypertensive crisis and anemia) leading to discontinuation of study drug and withdrawal from the study. The patient had a history of hypertension and developed a hypertensive crisis on day 9. Anemia (verbatim: worsening anemia) occurred on day 20. Both events were grade 3 SAEs. The patient was withdrawn from the study on day 21 and started on eculizumab 600 mg on the same day. The AEs resolved by day 37. The anemia was assessed by the investigator as possibly related to study drug, and the hypertensive crisis was assessed as not related to study drug.
[0240] During the initial evaluation period, one patient (0.9 years) experienced grade 2 nonsevere hypertension and the infusion was discontinued. This patient's systolic BP was 90 mmHg at screening, baseline, and day 15 (predose). No BP values were reported during the infusion on day 15. The infusion was interrupted for 10 minutes due to hypertension. The infusion was then resumed and the full dose was completed. This patient was started on antihypertensive medications. During subsequent visits, this patient's systolic BP ranged from 85 mmHg to 100 mmHg. As of the data cutoff date for this report, this adverse event was reported as resolving. Diastolic BP was in the normal range throughout the initial evaluation period, except on two occasions. Values were reported as 70 mmHg (day 54) and 55 mmHg (day 85).
[0241] Meningococcal infections were considered an AE of special interest (AESI) in this study. No meningococcal infections were reported during the initial evaluation period. No deaths were reported during the initial evaluation period.
[0242] G. Discussion and Overall Conclusions This was an interim analysis of data from 16 complement inhibitor-naïve pediatric patients with aHUS (2 patients aged <2 years, 7 patients aged 2 to 6 years, 5 patients aged 6 to 12 years, and 2 patients aged 12 to 18 years) who received ULTOMIRIS over a 26-week treatment period. Two patients withdrew early after one dose of study drug because of confirmed ineligibility based on central clinical laboratory results. Therefore, the FAS consisted of 14 patients.
[0243] These 14 pediatric patients were very ill at baseline: 13 / 14 (92.9%) were hospitalized at the time of first administration of study drug, 11 (78.6%) had advanced renal disease (CKD stage 4 or 5), and 10 (71.4%) had extrarenal signs or symptoms. Five patients (35.7%) were receiving dialysis at baseline, and 1 (7.1%) had received a kidney transplant prior to the study.
[0244] The primary endpoint of complete TMA remission at 26 weeks was achieved in 10 of 14 patients (71.4%; 95% CI: 41.9%, 91.6%). This compares favorably with the pivotal eculizumab trial in pediatric patients (C10-003), where the endpoint was achieved in 14 of 22 patients (64%; 95% CI: 41%, 83%). For the 10 patients who achieved complete TMA remission, this endpoint was achieved rapidly (median 30 days) and sustained over time. These results demonstrate the validity of the dosing regimen used in this study and the clinical benefit of immediate, complete, and sustained complement inhibition provided by ravulizumab treatment.
[0245] The majority of patients were aged 2-11 years, with two patients younger than 2 years. Interim PK / PD analysis showed that the loading dose was insufficient in the smallest patients (≥5 kg - <10 kg). One of these two patients withdrew on day 21 due to an SAE of hypertensive crisis and anemia. The investigator immediately started this patient on high-dose eculizumab. The protocol was subsequently amended to allow a larger loading dose for this weight group.
[0246] All 13 patients (93%) who completed the initial evaluation period achieved normalization of platelet counts by week 26. Additionally, 12 patients (86%) achieved normalization of LDH, and 11 patients (79%) achieved improvement in renal function (defined as a 25% improvement from baseline in serum creatinine). Improvement in renal function was also evident in a shift toward less severe CKD stage in all but two patients. The mean (SD) increase from baseline in EGFR was 84 (60) mL / min / 1.73 m2. Immediate, complete, and sustained suppression of free C5 was observed throughout the dosing interval. Additionally, of the five patients on dialysis at baseline, four were able to discontinue dialysis within a few weeks of starting ULTOMIRIS, and no patients required initiation of dialysis while on study. These functional improvements were reflected in clinically meaningful improvements in QoL, as indicated by higher FACIT fatigue scores over time.
[0247] Among 16 patients in the safety population, there were no findings of safety concern during the initial evaluation period. No deaths, meningococcal infections, or treatment-emergent immunogenicity were observed. The most frequent SAE was abdominal pain (2 patients). The weight-based dosing regimen of ULTOMIRIS appeared to be well tolerated in pediatric patients with aHUS who had not previously received complement inhibitor treatment.
[0248] Analysis of data from the initial evaluation period for the first 16 patients enrolled indicates that ULTOMIRIS provided immediate, complete, and sustained inhibition of terminal complement in this pediatric aHUS population. Complete TMA remission was achieved in 71.4% of patients by week 26, consistent with results observed in remission components as well as other secondary efficacy endpoints. Reduction in disease burden was also evident in improved QoL scores, with reduced need for dialysis and improved QoL scores. ULTOMIRIS was generally well tolerated in these complement inhibitor-naïve patients. In summary, this interim analysis indicates that weight-based dosing of ULTOMIRIS every 4 to 8 weeks in children treated for aHUS provided improvements in hematologic and renal endpoints without unanticipated safety concerns. The favorable benefit / risk profile of ULTOMIRIS in this study supports its use for the treatment of pediatric patients with aHUS.
[0249] Overview of Arrays [Table 27-1] [Table 27-2] [Table 27-3] [Table 27-4]
Claims
1. 1. A composition for treating a human pediatric patient with atypical hemolytic uremic syndrome (aHUS), comprising an anti-C5 antibody or antigen-binding fragment thereof, the antibody comprising a heavy chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO:14 and a light chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO:11, the composition comprising: (a) on day 1, i. 600 mg of the anti-C5 antibody or antigen-binding fragment thereof to a patient weighing 5 kg or more and less than 10 kg; ii. 600 mg of the anti-C5 antibody or antigen-binding fragment thereof to a patient weighing 10 kg or more and less than 20 kg; iii. 900 mg of the anti-C5 antibody or the antigen-binding fragment thereof to a patient weighing 20 kg or more and less than 30 kg; or iv. a single loading dose of 1200 mg of the anti-C5 antibody or antigen-binding fragment thereof to a patient weighing 30 kg or more and less than 40 kg; and (b) on day 15, i. 300 mg of the anti-C5 antibody or antigen-binding fragment thereof to a patient weighing 5 kg or more and less than 10 kg; ii. 600 mg of the anti-C5 antibody or antigen-binding fragment thereof to a patient weighing 10 kg or more and less than 20 kg; iii. 2100 mg of the anti-C5 antibody or the antigen-binding fragment thereof to a patient weighing 20 kg or more and less than 30 kg; or iv. A maintenance dose of 2700 mg of the anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 30 kg or more and less than 40 kg. Patients weighing less than 20 kg are given additional maintenance doses every 4 weeks thereafter, and patients weighing 20 kg or more are given additional maintenance doses every 8 weeks thereafter.
2. The anti-C5 antibody has an affinity dissociation constant (K) in the range of 0.1 nM to 1 nM at pH 7.4 and 25C. D 2. The composition of claim 1 , which binds to human C5 at the C5 domain.
3. The anti-C5 antibody is D The composition of claim 1 or 2, which binds to human C5 at ≧10 nM, pH 6.0 and 25C.
4. The composition is administered to a patient weighing 5 kg or more and less than 10 kg, (a) administered once on day 1 with a loading dose of 600 mg of the anti-C5 antibody or antigen-binding fragment thereof; and (b) a maintenance dose of 300 mg of the anti-C5 antibody or antigen-binding fragment thereof administered once on day 15, and every 4 weeks thereafter.
5. The composition is administered to a patient weighing 10 kg or more and less than 20 kg, (a) administered once on day 1 with a loading dose of 600 mg of the anti-C5 antibody or antigen-binding fragment thereof; and (b) a maintenance dose of 600 mg of the anti-C5 antibody or antigen-binding fragment thereof administered once on day 15, and every 4 weeks thereafter.
6. The composition is administered to a patient weighing 20 kg or more and less than 30 kg, (a) administered once on day 1 with a loading dose of 900 mg of the anti-C5 antibody or antigen-binding fragment thereof; and (b) a maintenance dose of 2100 mg of the anti-C5 antibody or antigen-binding fragment thereof administered once on day 15, and every 8 weeks thereafter.
7. The composition is administered to a patient weighing 30 kg or more and less than 40 kg, (a) administered once on day 1 with a loading dose of 1200 mg of the anti-C5 antibody or antigen-binding fragment thereof; and (b) a maintenance dose of 2700 mg of the anti-C5 antibody or antigen-binding fragment thereof administered once on day 15, and every 8 weeks thereafter.
8. The composition of any one of claims 1 to 7, wherein the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen-binding fragment thereof at or above 100 μg / mL.
9. The composition of any one of claims 1 to 8, wherein the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen-binding fragment thereof at or above 200 μg / mL.
10. The composition of any one of claims 1 to 9, wherein the treatment maintains a free C5 concentration of 0.309-0.5 μg / mL or less.
11. The composition of any one of claims 1 to 10, characterized in that the composition is administered at a dose of 300 mg or 600 mg of the anti-C5 antibody or antigen-binding fragment thereof every 4 weeks for up to 2 years after treatment.
12. The composition of any one of claims 1 to 11, characterized in that the composition is administered at a dose of 2100 mg or 2700 mg of the anti-C5 antibody or antigen-binding fragment thereof every 8 weeks for up to 2 years after treatment.
13. The composition according to any one of claims 1 to 12, characterized in that the composition is formulated for intravenous administration.
14. The composition of any one of claims 1 to 13, wherein the patient has not been previously treated with a complement inhibitor.
15. A composition described in any one of claims 1 to 13, wherein the patient has already been treated with a different anti-C5 antibody or antigen-binding fragment thereof.
16. The composition described in any one of claims 1 to 13, wherein the patient is already treated with eculizumab.
17. The composition of any one of claims 1 to 16, wherein the patient is under 18 years of age.
18. The composition of any one of claims 1 to 17, wherein the treatment is a dosing cycle comprising a total of 26 weeks of treatment.
19. The composition of any one of claims 1 to 18, wherein the treatment results in terminal complement inhibition.
20. The composition of any one of claims 1 to 19, wherein the treatment results in a complete thrombotic microangiopathy (TMA) response.
21. The composition of any one of claims 1 to 20, wherein the treatment results in a 25% or greater decrease in serum creatinine levels compared to baseline.
22. The composition of any one of claims 1 to 21, wherein the treatment results in an increase in platelet count compared to baseline.
23. 23. The composition of any one of claims 1 to 22, wherein the treatment results in a decrease in hemolysis compared to a baseline as assessed by lactate dehydrogenase (LDH) levels.
24. 2. The composition of claim 1, wherein the treatment results in a reduction or cessation of at least one therapeutic marker selected from the group consisting of severe hypertension, proteinuria, uremia, fatigue, fatigue, irritability, thrombocytopenia, microangiopathic hemolytic anemia, and renal dysfunction compared to a baseline.
25. 25. The composition of any one of claims 1 to 24, wherein the treatment results in a shift to normal levels of a marker selected from the group consisting of Factor Ba, soluble tumor necrosis factor receptor 1 (sTNFR1), soluble vascular adhesion molecule 1 (sVCAM1), thrombomodulin, D-dimer, and cystatin C, as compared to a baseline.
26. The composition of any one of claims 1 to 25, wherein the treatment results in a reduction in the need for blood transfusions compared to a baseline.
27. The composition of any one of claims 1 to 26, wherein the treatment results in a reduction in major adverse vascular events (MAVE) compared to a baseline.
28. 28. The composition of any one of claims 1 to 27, wherein the treatment produces a change from baseline in quality of life as assessed via the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale, 4th Edition, or the European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30 Scale, compared to baseline.
29. 1. A kit for treating atypical hemolytic uremic syndrome (aHUS) in a human pediatric patient, comprising: (a) a dose of an anti-C5 antibody or antigen-binding fragment thereof, the antibody comprising a heavy chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 14 and a light chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 11; and (b) instructions for using the anti-C5 antibody or antigen-binding fragment thereof in the method of claim 1.
30. The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 5 kg or more and less than 10 kg. (a) administered once on day 1 at a loading dose of 600 mg; and (b) a maintenance dose of 300 mg administered once on day 15, and every 4 weeks thereafter.
31. The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 10 kg or more and less than 20 kg. (a) administered once on day 1 at a loading dose of 600 mg; and (b) a maintenance dose of 600 mg administered once on day 15, and every 4 weeks thereafter.
32. The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 20 kg or more and less than 30 kg. (a) administered once on day 1 at a loading dose of 900 mg; and (b) a maintenance dose of 2100 mg administered once on day 15, and every 8 weeks thereafter.
33. The anti-C5 antibody or antigen-binding fragment thereof is administered to a patient weighing 30 kg or more and less than 40 kg. (a) administered once on day 1 at a loading dose of 1200 mg; and (b) a maintenance dose of 2700 mg administered once on day 15, and every 8 weeks thereafter.
34. 10. The composition of claim 1, wherein the antibody is determined to be safe, tolerable, effective, and sufficiently non-immunogenic after multiple IV administrations in aHUS patients.
35. A kit described in any one of claims 29 to 33, wherein the patient has already been treated with a different anti-C5 antibody or antigen-binding fragment thereof.
36. The kit described in any one of claims 29 to 33, wherein the patient is already being treated with eculizumab.
37. The composition of claim 1, wherein the anti-C5 antibody is ravulizumab.
38. The kit of claim 29, wherein the anti-C5 antibody is ravulizumab.
Citation Information
Patent Citations
Dosage and administration of Anti-c5 antibodies for treatment
WO2017123636A1
